

ALLERGAN INC
Form 10-Q
November 05, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the Quarterly Period Ended September 30, 2013

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

Commission File Number 1-10269

Allergan, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation or Organization)

95-1622442

(I.R.S. Employer Identification No.)

2525 Dupont Drive

Irvine, California

(Address of Principal Executive Offices)

(714) 246-4500

(Registrant's Telephone Number, Including Area Code)

92612

(Zip Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of October 31, 2013, there were 307,554,060 shares of common stock outstanding (including 10,391,641 shares held in treasury).

ALLERGAN, INC.
 FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2013
 INDEX

	Page
<u>PART I — FINANCIAL INFORMATION</u>	
<u>Item 1 — Financial Statements</u>	
(A) <u>Unaudited Condensed Consolidated Statements of Earnings — Three and Nine Months Ended September 30, 2013 and September 30, 2012</u>	3
(B) <u>Unaudited Condensed Consolidated Statements of Comprehensive Income — Three and Nine Months Ended September 30, 2013 and September 30, 2012</u>	4
(C) <u>Unaudited Condensed Consolidated Balance Sheets — September 30, 2013 and December 31, 2012</u>	5
(D) <u>Unaudited Condensed Consolidated Statements of Cash Flows — Nine Months Ended September 30, 2013 and September 30, 2012</u>	6
(E) <u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	7
<u>Item 2 — Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	29
<u>Item 3 — Quantitative and Qualitative Disclosures About Market Risk</u>	53
<u>Item 4 — Controls and Procedures</u>	57
<u>PART II — OTHER INFORMATION</u>	
<u>Item 1 — Legal Proceedings</u>	58
<u>Item 1A — Risk Factors</u>	58
<u>Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds</u>	58
<u>Item 3 — Defaults Upon Senior Securities</u>	58
<u>Item 4 — Mine Safety Disclosures</u>	58
<u>Item 5 — Other Information</u>	58
<u>Item 6 — Exhibits</u>	58
<u>SIGNATURE</u>	59
<u>EXHIBIT INDEX</u>	60

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

ALLERGAN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(in millions, except per share amounts)

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
Revenues:				
Product net sales	\$ 1,528.4	\$ 1,353.7	\$ 4,537.9	\$ 4,101.5
Other revenues	30.3	22.8	78.1	73.0
Total revenues	1,558.7	1,376.5	4,616.0	4,174.5
Operating costs and expenses:				
Cost of sales (excludes amortization of intangible assets)	192.2	182.9	591.2	568.2
Selling, general and administrative	589.3	522.9	1,804.0	1,650.8
Research and development	257.6	289.8	772.9	737.5
Amortization of intangible assets	28.8	22.8	88.5	67.2
Restructuring charges	0.6	0.6	4.9	1.5
Operating income	490.2	357.5	1,354.5	1,149.3
Non-operating income (expense):				
Interest income	1.5	1.9	5.1	4.8
Interest expense	(19.4) (15.9) (56.8) (48.8
Other, net	(15.5) (9.2) (13.0) (19.3
	(33.4) (23.2) (64.7) (63.3
Earnings from continuing operations before income taxes	456.8	334.3	1,289.8	1,086.0
Provision for income taxes	123.9	81.4	329.9	307.6
Earnings from continuing operations	332.9	252.9	959.9	778.4
Discontinued operations:				
Earnings (loss) from discontinued operations, net of applicable income tax expense (benefit) of \$2.7 million and \$(1.2) million for the three months ended September 30, 2013 and 2012, respectively, and \$6.4 million and \$(1.0) million for the nine months ended September 30, 2013 and 2012, respectively	5.5	(2.3) 13.1	(1.1
Expected loss on sale of discontinued operations, net of applicable income tax benefit of \$21.1 million and \$108.3 million for the three and nine months ended September 30, 2013, respectively	(37.6) —	(296.6) —
Discontinued operations	(32.1) (2.3) (283.5) (1.1
Net earnings	300.8	250.6	676.4	777.3
Net earnings attributable to noncontrolling interest	1.0	1.2	4.2	2.7

Edgar Filing: ALLERGAN INC - Form 10-Q

Net earnings attributable to Allergan, Inc.	\$299.8	\$ 249.4	\$672.2	\$ 774.6
Basic earnings per share attributable to Allergan, Inc. stockholders:				
Continuing operations	\$ 1.12	\$ 0.84	\$3.22	\$ 2.57
Discontinued operations	(0.11) (0.01) (0.95) (0.01
Net basic earnings per share attributable to Allergan, Inc. stockholders	\$ 1.01	\$ 0.83	\$2.27	\$ 2.56
Diluted earnings per share attributable to Allergan, Inc. stockholders:				
Continuing operations	\$ 1.10	\$ 0.82	\$3.17	\$ 2.52
Discontinued operations	(0.10) —	(0.94) —
Net diluted earnings per share attributable to Allergan, Inc. stockholders	\$ 1.00	\$ 0.82	\$2.23	\$ 2.52

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

ALLERGAN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in millions)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
Net earnings	\$ 300.8	\$ 250.6	\$ 676.4	\$ 777.3
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustments	31.0	14.9	(8.1)	(2.1)
Amortization of deferred holding gains on derivatives designated as cash flow hedges included in net earnings, net of income tax benefit of \$0.1 million for the three months ended September 30, 2013 and 2012, respectively, and \$0.4 million for the nine months ended September 30, 2013 and 2012, respectively	(0.2)	(0.2)	(0.6)	(0.6)
Other comprehensive income (loss)	30.8	14.7	(8.7)	(2.7)
Total comprehensive income	331.6	265.3	667.7	774.6
Comprehensive income attributable to noncontrolling interest	1.8	2.1	3.0	3.4
Comprehensive income attributable to Allergan, Inc.	\$ 329.8	\$ 263.2	\$ 664.7	\$ 771.2

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

ALLERGAN, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share data)

	September 30, 2013	December 31, 2012
ASSETS		
Current assets:		
Cash and equivalents	\$ 2,686.3	\$ 2,701.8
Short-term investments	524.6	260.6
Trade receivables, net	908.2	739.0
Inventories	280.0	272.3
Other current assets	440.0	448.6
Assets held for sale	93.3	512.6
Total current assets	4,932.4	4,934.9
Investments and other assets	191.6	192.1
Deferred tax assets	120.2	206.9
Property, plant and equipment, net	877.0	851.5
Goodwill	2,334.0	2,133.8
Intangibles, net	1,689.4	860.1
Total assets	\$ 10,144.6	\$ 9,179.3
LIABILITIES AND EQUITY		
Current liabilities:		
Notes payable	\$ 37.2	\$ 48.8
Accounts payable	267.8	232.2
Accrued compensation	241.9	222.4
Other accrued expenses	632.6	586.8
Income taxes	16.9	—
Liabilities held for sale	3.3	5.3
Total current liabilities	1,199.7	1,095.5
Long-term debt	2,101.5	1,512.4
Other liabilities	730.3	708.8
Commitments and contingencies		
Equity:		
Allergan, Inc. stockholders' equity:		
Preferred stock, \$.01 par value; authorized 5,000,000 shares; none issued	—	—
Common stock, \$.01 par value; authorized 500,000,000 shares; issued 307,554,060 shares as of September 30, 2013 and 307,537,860 shares as of December 31, 2012	3.1	3.1
Additional paid-in capital	3,005.2	2,900.6
Accumulated other comprehensive loss	(252.1)	(244.6)
Retained earnings	4,363.6	3,832.1
	7,119.8	6,491.2
Less treasury stock, at cost (10,407,370 shares as of September 30, 2013 and 7,213,757 shares as of December 31, 2012)	(1,033.9)	(654.1)
Total stockholders' equity	6,085.9	5,837.1
Noncontrolling interest	27.2	25.5
Total equity	6,113.1	5,862.6
Total liabilities and equity	\$ 10,144.6	\$ 9,179.3

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents

ALLERGAN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

	Nine Months Ended	
	September 30, 2013	September 30, 2012
Cash flows from operating activities:		
Net earnings	\$676.4	\$ 777.3
Non-cash items included in net earnings:		
Depreciation and amortization	195.1	191.4
Amortization of original issue discount and debt issuance costs	1.9	1.4
Amortization of net realized gain on interest rate swaps	(10.8)	(4.2)
Deferred income tax benefit	(134.1)	(40.6)
Loss on disposal and impairment of assets	3.9	5.0
Unrealized (gain) loss on derivative instruments	(4.3)	15.2
Expense of share-based compensation plans	84.6	79.7
Expected loss on sale of discontinued operations	404.9	—
Expense from changes in fair value of contingent consideration	4.8	15.8
Restructuring charges	4.9	4.7
Loss on investment	3.7	—
Changes in operating assets and liabilities:		
Trade receivables	(173.4)	(151.1)
Inventories	(22.6)	(12.2)
Other current assets	23.2	(19.4)
Other non-current assets	(8.2)	46.5
Accounts payable	22.6	13.6
Accrued expenses	58.1	114.0
Income taxes	20.4	38.4
Other liabilities	29.0	24.5
Net cash provided by operating activities	1,180.1	1,100.0
Cash flows from investing activities:		
Purchases of short-term investments	(644.5)	(704.6)
Acquisitions, net of cash acquired	(892.1)	(3.1)
Additions to property, plant and equipment	(97.4)	(98.1)
Additions to capitalized software	(8.6)	(7.5)
Additions to intangible assets	(0.3)	(4.1)
Proceeds from maturities of short-term investments	380.5	604.7
Proceeds from sale of property, plant and equipment	0.4	1.3
Net cash used in investing activities	(1,262.0)	(211.4)
Cash flows from financing activities:		
Dividends to stockholders	(44.6)	(45.4)
Payments to acquire treasury stock	(649.3)	(723.3)
Payments of contingent consideration	(11.1)	(5.1)
Net repayments of notes payable	(11.6)	(43.1)
Debt issuance costs	(4.8)	—
Proceeds from issuance of senior notes, net of discount	598.5	—

Edgar Filing: ALLERGAN INC - Form 10-Q

Sale of stock to employees	160.1	153.9
Excess tax benefits from share-based compensation	33.6	24.5
Net cash provided by (used in) financing activities	70.8	(638.5)
Effect of exchange rate changes on cash and equivalents	(4.4)	(1.2)
Net (decrease) increase in cash and equivalents	(15.5)	248.9
Cash and equivalents at beginning of period	2,701.8	2,406.1
Cash and equivalents at end of period	\$2,686.3	\$ 2,655.0
Supplemental disclosure of cash flow information		
Cash paid for:		
Interest, net of amount capitalized	\$55.0	\$ 39.9
Income taxes, net of refunds	\$290.8	\$ 261.3
See accompanying notes to unaudited condensed consolidated financial statements.		

6

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary (consisting only of normal recurring accruals) to present fairly the financial information contained therein. These statements do not include all disclosures required by accounting principles generally accepted in the United States of America (GAAP) for annual periods and should be read in conjunction with the Company's audited consolidated financial statements and related notes for the year ended December 31, 2012. The Company prepared the unaudited condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. The results of operations for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013 or any other period(s).

Reclassifications

Certain reclassifications of prior year amounts have been made to conform with the current year presentation. On February 1, 2013, the Company completed its previously announced review of strategic options for maximizing the value of its obesity intervention business, and formally committed to pursue a sale of that business unit. Accordingly, beginning in the first quarter of 2013, the Company has reported the financial results from that business unit as discontinued operations in the consolidated statements of earnings and has classified the related assets and liabilities as held for sale in the consolidated balance sheet. The prior period consolidated statements of earnings and consolidated balance sheet as of December 31, 2012 have been retrospectively revised to reflect the obesity intervention business unit as discontinued operations and the related assets and liabilities as held for sale.

Recently Adopted Accounting Standards

In February 2013, the Financial Accounting Standards Board (FASB) issued an accounting standards update that requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amounts are required to be reclassified in their entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance became effective for reporting periods beginning after December 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013 and had no significant reclassifications out of accumulated other comprehensive income to net income during the third quarter and the first nine months of 2013.

In July 2012, the FASB issued an accounting standards update that gives an entity the option to first assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. This guidance became effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013. The adoption did not have a material impact on the Company's consolidated financial statements.

New Accounting Standards Not Yet Adopted

In July 2013, the FASB issued an accounting standards update that requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. This guidance will be effective for fiscal years beginning after December 15, 2013, which will be the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.

In March 2013, the FASB issued an accounting standards update that provides guidance on the accounting for the cumulative translation adjustment (CTA) upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. Under this guidance, an entity should recognize the CTA in

earnings based on meeting certain criteria, including when it ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity or upon a sale or transfer that results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets resides. This guidance will be effective for fiscal years beginning on or after December 15, 2013, which will be

7

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.

Note 2: Acquisitions and Collaborations

MAP Acquisition

On March 1, 2013, the Company completed the acquisition of MAP Pharmaceuticals, Inc. (MAP), a biopharmaceutical company based in the United States focused on developing and commercializing new therapies in neurology, including Levadex[®], an orally inhaled drug for the potential acute treatment of migraine in adults, for an aggregate purchase price of approximately \$871.7 million, net of cash acquired. The acquisition was funded from a combination of current cash and equivalents and short-term investments.

The Company recognized tangible and intangible assets acquired and liabilities assumed in connection with the MAP acquisition based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recognized as goodwill. The goodwill acquired in the MAP acquisition is not deductible for federal income tax purposes. In connection with the acquisition, the Company acquired assets with a fair value of \$1,232.9 million, consisting of current assets of \$2.3 million, property, plant and equipment of \$7.7 million, other non-current assets of \$0.3 million, deferred tax assets of \$136.5 million, intangible assets of \$915.6 million and goodwill of \$170.5 million, and assumed liabilities of \$361.2 million, consisting of current liabilities of \$27.4 million and deferred tax liabilities of \$333.8 million.

The intangible assets consist of an in-process research and development asset of \$683.5 million associated with Levadex[®], which is currently under review with the U.S. Food and Drug Administration (FDA), and a core technology asset of \$232.1 million associated with MAP's proprietary Tempo[®] delivery system that has an estimated useful life of 15 years.

Goodwill represents the excess of the MAP purchase price over the sum of the amounts assigned to assets acquired less liabilities assumed. The MAP acquisition broadens the Company's product offering for the treatment of migraine headaches and MAP's proprietary drug particle and inhalation technology provides the potential for new product development opportunities, which the Company believes support the amount of goodwill recognized as a result of the purchase price paid for MAP, in relation to other acquired tangible and intangible assets.

Exemplar Acquisition

On April 12, 2013, the Company completed the acquisition of Exemplar Pharma, LLC (Exemplar), a third party contract manufacturer for MAP's Tempo[®] delivery system, for an aggregate purchase price of approximately \$16.1 million, net of cash acquired. Prior to the acquisition, the Company also had a \$1.9 million payable to Exemplar, which was effectively settled upon the acquisition. In connection with the acquisition, the Company acquired assets with a fair value of \$16.6 million, consisting of current assets of \$0.5 million, property, plant and equipment of \$2.1 million and goodwill of \$14.0 million, and assumed current liabilities of \$0.5 million. The goodwill acquired in the Exemplar acquisition is deductible for federal income tax purposes.

SkinMedica Acquisition

On December 19, 2012, the Company completed the acquisition of SkinMedica, Inc. (SkinMedica), a privately-held aesthetics skin care company based in the United States focused on developing and commercializing products that improve the appearance of skin, for an upfront payment of \$348.9 million, net of cash acquired. The Company may also be required to pay up to an additional \$25.0 million, contingent upon acquired products achieving certain sales milestones. The estimated fair value of the contingent consideration as of the acquisition date was \$2.2 million. The acquisition was funded from the Company's cash and equivalents balances.

The Company recognized tangible and intangible assets acquired, liabilities assumed and the contingent consideration liability in connection with the SkinMedica acquisition based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recognized as goodwill. The goodwill acquired in the SkinMedica acquisition is not deductible for federal income tax purposes. In connection with the

acquisition, the Company acquired assets with a fair value of \$438.3 million, consisting of current assets of \$30.2 million, property, plant and equipment of \$6.6 million, deferred tax assets of \$40.6 million, intangible assets of \$200.9 million and goodwill of \$160.0 million, and assumed liabilities of \$87.2 million, consisting of current liabilities of \$11.2 million and deferred tax liabilities of \$76.0 million. As of September 30, 2013, the total estimated fair value of the contingent consideration of \$2.2 million was included in "Other liabilities."

The intangible assets consist of developed technology, customer relationships, trademarks and an in-process research and

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

development asset. Acquired developed technology assets consist of the currently marketed SkinMedica® family of products, including the TNS (Tissue Nutrient Solution) products, Vaniqua®, Lytera® and scar recovery gel. The amounts assigned to each class of intangible assets and the related weighted average amortization periods are summarized in the following table:

	Value of Intangible Assets Acquired (in millions)	Weighted Average Amortization Period (in years)
Developed technology	\$87.5	10.6
Customer relationships	50.6	2.7
Trademarks	62.5	15.0
In-process research and development	0.3	—
	\$200.9	

Goodwill represents the excess of the SkinMedica purchase price over the sum of the amounts assigned to assets acquired less liabilities assumed. The SkinMedica acquisition complements the Company's existing facial aesthetics business and enables the Company to take a leadership position in the growing physician-dispensed topical aesthetics skin care market and to create certain sales and marketing operating synergies, which the Company believes support the amount of goodwill recognized as a result of the purchase price paid for SkinMedica, in relation to other acquired tangible and intangible assets.

Purchase of Distributor's Business in Russia

On February 1, 2012, the Company terminated its existing distributor agreement in Russia and completed the purchase from its distributor of all assets related to the selling and distribution of the Company's products in Russia. The termination of the existing distributor agreement and purchase of the commercial assets enabled the Company to initiate direct operations for its medical aesthetics and neurosciences businesses in Russia.

The purchase of the commercial assets was accounted for as a business combination. In connection with the purchase of the assets, the Company paid \$3.1 million, net of a \$6.6 million pre-existing net receivable from the distributor, and is also required to pay additional contingent consideration based on certain contractual obligations of the former distributor over a two year period from the acquisition date. The estimated fair value of the contingent consideration as of the acquisition date was \$4.7 million. The Company acquired assets with a fair value of \$14.4 million, consisting of inventories of \$2.0 million, intangible assets of \$8.6 million and goodwill of \$3.8 million. No liabilities were assumed in connection with the purchase. The intangible assets relate to customer relationships that have an estimated useful life of three years and other contractual rights that have an estimated useful life of two years. As of September 30, 2013, the total estimated fair value of the contingent consideration of \$2.0 million was included in "Other accrued expenses."

The Company believes that the fair values assigned to the assets acquired, liabilities assumed and the contingent consideration liabilities were based on reasonable assumptions. The Company's fair value estimates may change during the allowable measurement period, which is up to one year from the acquisition date, if additional information becomes available.

Molecular Partners AG Collaboration

On August 21, 2012, the Company announced that it entered into two separate agreements with Molecular Partners AG to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases. The first agreement is an exclusive license agreement for the design, development and commercialization of a potent dual anti-VEGF-A/PDGF-B DARPin® (MP0260) and its corresponding backups for the treatment of exudative (wet) age-related macular degeneration and related conditions. The second agreement is an exclusive discovery alliance agreement under which the parties are collaborating to design and develop DARPin®

products against selected targets that are implicated in causing serious diseases of the eye. Under the terms of the agreements, the Company made combined upfront payments of \$62.5 million to Molecular Partners AG in August 2012, which were recorded as research and development (R&D) expense in the third quarter of 2012 because the technology has not yet achieved regulatory approval. The terms of the agreements also include potential future development, regulatory and sales milestone payments to Molecular Partners AG of up to \$1.4 billion, as well as potential future royalty payments.

On May 4, 2011, the Company announced a license agreement with Molecular Partners AG pursuant to which the Company obtained exclusive global rights in the field of ophthalmology for MP0112, a Phase II proprietary therapeutic anti-VEGF DARPin®

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

protein under investigation for the treatment of retinal diseases. Under the terms of the agreement, the Company made a \$45.0 million upfront payment to Molecular Partners AG in May 2011, which was recorded as R&D expense in the second quarter of 2011 because the technology has not yet achieved regulatory approval. The terms of the agreement also include potential future development, regulatory and sales milestone payments to Molecular Partners AG of up to \$375.0 million, as well as potential future royalty payments.

Under the exclusive license agreements, subject to certain limited exceptions, the Company is responsible for and incurs all expenses related to the conduct of all development activities; the preparation, filing and maintaining of all regulatory materials; the planning and implementation of all commercial activities; and all manufacturing activities. Under the exclusive discovery alliance agreement, during the research term each party will bear all expenses it incurs to conduct its respective activities, subject to certain limited exceptions. Milestone payments made by the Company to Molecular Partners AG pursuant to these agreements prior to the achievement of regulatory approval are immediately recognized and recorded as R&D expense. Milestone payments, if any, that are made upon, or subsequent to, regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining commercial life of the underlying technology.

Other Collaborations

On September 25, 2013, the Company announced that it had entered into a license agreement with Medytox, Inc. (Medytox) pursuant to which, upon closing, the Company will pay Medytox an upfront payment of \$65.0 million and Medytox will grant the Company exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. The terms of the agreement also include potential future development milestone payments of up to \$116.5 million and potential future sales milestone payments of up to \$180.5 million, as well as potential future royalty payments. The closing of the transaction is contingent on obtaining certain government approvals.

On September 10, 2013, the Company entered into a license and collaboration agreement with a third party pursuant to which the Company obtained exclusive global rights to research, manufacture and commercialize certain technologies for the treatment of ocular disease. Under the terms of the agreement, the Company made a \$6.5 million upfront payment, which was recorded as R&D expense in the third quarter of 2013 because the technology has not yet achieved regulatory approval. The terms of the agreement also include potential future payments to the third party related to the Company's achievement of development, regulatory and sales milestone events, as well as potential future royalty payments.

In March 2010, the Company and Serenity Pharmaceuticals, LLC (Serenity) entered into an agreement for the license, development and commercialization of a Phase III investigational drug currently in clinical development for the treatment of nocturia, a common urological disorder in adults characterized by frequent urination at night time. In conjunction with the agreement, the Company made an upfront payment to Serenity of \$43.0 million. In December 2010, the Company and Serenity executed a letter agreement which specified terms and conditions governing additional development activities for a new Phase III trial which were not set forth in the original agreement. Under the letter agreement, the Company agreed to share 50% of the cost of additional development activities for the new Phase III trial. Since the Company is providing a significant amount of the funding for the new Phase III trial, it determined that Serenity is a variable interest entity (VIE). However, the Company determined that it is not the primary beneficiary of the VIE because it does not possess the power to direct Serenity's research and development activities, which are the activities that most significantly impact Serenity's economic performance. The Company's maximum future exposure to loss is the Company's share of additional development activities.

In connection with various business development transactions where the Company has outlicensed its technology to third parties, the Company has aggregate potential future milestone receipts of approximately \$35.7 million as of September 30, 2013, none of which are individually significant. Of that amount, approximately \$3.5 million relates to achievement of certain development milestones, approximately \$12.0 million relates to achievement of certain regulatory milestones, and approximately \$20.2 million relates to achievement of certain commercial sales milestones.

Due to the challenges associated with developing and obtaining approval for pharmaceutical products, there is substantial uncertainty whether any of the future milestones will be achieved. The Company evaluates whether milestone payments are substantive based on the facts and circumstances associated with each milestone payment.

Note 3: Discontinued Operations

On February 1, 2013, the Company completed its previously announced review of strategic options for maximizing the value of its obesity intervention business, and formally committed to pursue a sale of that business unit. As a result of the Company's approved plan to pursue a sale of its obesity intervention business unit, beginning in the first quarter of 2013, the Company has

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

reported the financial results from that business unit in discontinued operations in its consolidated statements of earnings and has classified the related assets and liabilities as held for sale in its consolidated balance sheet. The prior period consolidated statements of earnings and consolidated balance sheet as of December 31, 2012 have been retrospectively revised to reflect the obesity intervention business unit as discontinued operations and the related assets and liabilities as held for sale.

The results of operations from discontinued operations presented below include certain allocations that management believes fairly reflect the utilization of services provided to the obesity intervention business. The allocations do not include amounts related to general corporate administrative expenses or interest expense. Therefore, the results of operations from the obesity intervention business unit do not necessarily reflect what the results of operations would have been had the business operated as a stand-alone entity.

The following table summarizes the results of operations from discontinued operations:

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Product net sales	\$29.3	\$ 37.4	\$94.5	\$ 122.7
Operating costs and expenses:				
Cost of sales (excludes amortization of intangible assets)	5.4	5.8	15.9	18.1
Selling, general and administrative	14.4	18.0	44.8	59.8
Research and development	1.3	3.5	4.0	12.8
Amortization of intangible assets	—	10.4	10.3	30.9
Restructuring charges	—	3.2	—	3.2
Earnings (loss) from discontinued operations before income taxes	\$8.2	\$ (3.5)	\$19.5	\$ (2.1)
Earnings (loss) from discontinued operations, net of income taxes	\$5.5	\$ (2.3)	\$13.1	\$ (1.1)

In the first quarter of 2013, the Company also reported a separate estimated pre-tax disposal loss of \$346.2 million (\$259.0 million after tax) related to the obesity intervention business unit from the write-down of the net assets held for sale to their estimated fair value less costs to sell. The Company determined the estimated fair value of the net assets held for sale based on a range of indicative purchase prices received from prospective buyers participating in an orderly sales process. The net assets held for sale include a portion of the Company's medical devices reporting unit's goodwill allocated to the obesity intervention business based on the relative fair value as of February 1, 2013 of that business to the portion of the medical devices reporting unit that the Company will retain. During the first quarter of 2013, the Company tested the remaining goodwill of the medical devices reporting unit for impairment and concluded that no impairment was indicated.

On October 28, 2013, the Company entered into a definitive agreement to sell its obesity intervention business to Apollo Endosurgery, Inc. (Apollo) for an upfront cash payment of \$75.0 million, subject to certain adjustments, and certain additional consideration, including a \$15.0 million minority equity interest in Apollo and contingent consideration of up to \$20.0 million to be paid upon the achievement of certain regulatory and sales milestones. The transaction is expected to close in 2013, subject to customary closing conditions. In the third quarter of 2013, the Company recorded an additional pre-tax disposal loss of \$58.7 million (\$37.6 million after tax) from the write-down of the net assets held for sale to their estimated fair value based on the terms of the sale agreement.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The following table summarizes the assets and liabilities held for sale related to the Company's obesity intervention business unit as of September 30, 2013 and December 31, 2012:

	September 30, 2013	December 31, 2012
	(in millions)	
Assets:		
Trade receivables, net	\$22.2	\$ 25.2
Inventories	10.1	10.6
Property, plant and equipment, net	1.2	1.4
Goodwill	105.7	105.7
Intangibles, net	358.7	369.0
Other assets	0.3	0.7
Valuation allowance	(404.9) —
Total assets held for sale	\$93.3	\$ 512.6
Liabilities:		
Accounts payable	\$0.8	\$ 0.9
Accrued expenses	2.4	4.1
Other liabilities	0.1	0.3
Total liabilities held for sale	\$3.3	\$ 5.3

Note 4: Restructuring Charges and Integration Costs

In connection with the March 2013 acquisition of MAP, the April 2013 acquisition of Exemplar and the December 2012 acquisition of SkinMedica, the Company initiated restructuring activities to integrate the operations of the acquired businesses with the Company's operations and to capture synergies through the centralization of certain research and development, manufacturing, general and administrative and commercial functions. The restructuring charges primarily consist of employee severance and other one-time termination benefits for approximately 111 people. In the first quarter of 2013, the Company recorded \$4.3 million of restructuring charges. In the second quarter of 2013, the Company recorded a \$0.9 million restructuring charge reversal. In the third quarter of 2013, the Company recorded an additional \$0.6 million of restructuring charges.

Included in the nine month period ended September 30, 2013 are \$0.9 million of restructuring charges for employee severance and other one-time termination benefits related to the realignment of various business functions initiated in 2013. Included in the three and nine month periods ended September 30, 2012 are \$0.7 million of restructuring charges for employee severance and other one-time termination benefits related to the realignment of various business functions initiated in 2012. Included in the three and nine month periods ended September 30, 2012 are a \$0.1 million restructuring charge reversal and \$0.8 million of restructuring charges, respectively, related to restructuring activities initiated in prior years.

Included in the three month period ended September 30, 2013 are \$3.4 million of SG&A expenses and in the nine month period ended September 30, 2013 \$0.1 million of cost of sales and \$18.5 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. Included in the three month period ended September 30, 2012 are \$0.1 million of SG&A expenses and in the nine month period ended September 30, 2012 \$0.1 million of cost of sales and \$0.6 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. For the nine month period ended September 30, 2013, these costs primarily consist of investment banking and legal fees. In addition, included in the three month period ended September 30, 2013 are \$1.4 million of SG&A expenses and \$0.2 million of R&D expenses and in the nine month period ended September 30, 2013 \$1.6 million of SG&A

expenses and \$0.9 million of R&D expenses related to the realignment of various business functions. Included in the three month period ended September 30, 2012 are \$0.3 million of SG&A expenses and in the nine month period ended September 30, 2012 \$0.8 million of SG&A expenses and \$0.3 million of R&D expenses related to the realignment of various business functions. The SG&A and R&D expenses related to the realignment of various business functions primarily consist of one-time termination benefits earned based on specified retention periods and losses on the disposal of fixed assets.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Note 5: Intangibles and Goodwill

Intangibles

At September 30, 2013 and December 31, 2012, the components of intangibles and certain other related information were as follows:

	September 30, 2013			December 31, 2012		
	Gross Amount (in millions)	Accumulated Amortization	Weighted Average Amortization Period (in years)	Gross Amount (in millions)	Accumulated Amortization	Weighted Average Amortization Period (in years)
Amortizable Intangible Assets:						
Developed technology	\$646.5	\$(328.6)) 11.1	\$644.2	\$(284.5)) 11.1
Customer relationships	54.6	(16.7)) 2.7	54.5	(1.2)) 2.7
Licensing	185.9	(164.2)) 9.3	185.9	(157.8)) 9.3
Trademarks	89.5	(28.4)) 12.4	87.9	(25.3)) 12.3
Core technology	326.9	(61.0)) 14.8	93.8	(46.5)) 14.4
Other	42.3	(20.2)) 6.3	43.9	(14.1)) 6.4
	1,345.7	(619.1)) 11.3	1,110.2	(529.4)) 10.6
Unamortizable Intangible Assets:						
In-process research and development	962.8	—		279.3	—	
	\$2,308.5	\$(619.1))	\$1,389.5	\$(529.4))

Developed technology consists primarily of current product offerings, primarily breast aesthetics products, dermal fillers, skin care products and eye care products acquired in connection with business combinations, asset acquisitions and initial licensing transactions for products previously approved for marketing. Customer relationship assets consist of the estimated value of relationships with customers acquired in connection with business combinations. Licensing assets consist primarily of capitalized payments to third party licensors related to the achievement of regulatory approvals to commercialize products in specified markets and upfront payments associated with royalty obligations for products that have achieved regulatory approval for marketing. Core technology consists of a drug delivery technology acquired in connection with the Company's 2013 acquisition of MAP, proprietary technology associated with silicone gel breast implants acquired in connection with the Company's 2006 acquisition of Inamed Corporation, dermal filler technology acquired in connection with the Company's 2007 acquisition of Groupe Corneal Laboratoires and a drug delivery technology acquired in connection with the Company's 2003 acquisition of Oculex Pharmaceuticals, Inc. Other intangible assets consist primarily of acquired product registration rights, distributor relationships, distribution rights, government permits and non-compete agreements. The in-process research and development assets consist primarily of an orally inhaled drug for the potential acute treatment of migraine in adults acquired in connection with the Company's 2013 acquisition of MAP, a novel compound to treat erythema associated with rosacea acquired in connection with the Company's 2011 acquisition of Vicept Therapeutics, Inc. that is currently under development and an intangible asset associated with technology acquired in connection with the Company's 2011 acquisition of Alacer Biomedical, Inc. that is not yet commercialized.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The following table provides amortization expense by major categories of intangible assets for the three and nine month periods ended September 30, 2013 and 2012, respectively:

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
	(in millions)			
Developed technology	\$ 14.3	\$ 13.6	\$ 42.9	\$ 39.7
Customer relationships	5.1	0.3	15.3	0.8
Licensing	0.7	5.1	6.7	15.3
Trademarks	1.1	0.1	3.3	0.3
Core technology	5.5	1.6	13.9	4.9
Other	2.1	2.1	6.4	6.2
	\$ 28.8	\$ 22.8	\$ 88.5	\$ 67.2

Amortization expense related to acquired intangible assets generally benefits multiple business functions within the Company, such as the Company's ability to sell, manufacture, research, market and distribute products, compounds and intellectual property. The amount of amortization expense excluded from cost of sales consists primarily of amounts amortized with respect to developed technology and licensing intangible assets.

Estimated amortization expense is \$117.7 million for 2013, \$113.1 million for 2014, \$99.5 million for 2015, \$77.6 million for 2016 and \$56.8 million for 2017.

Goodwill

Changes in the carrying amount of goodwill by operating segment through September 30, 2013 were as follows:

	Specialty	Medical	Total
	Pharmaceuticals	Devices	
	(in millions)		
Balance at December 31, 2012	\$ 299.8	\$ 1,834.0	\$ 2,133.8
MAP acquisition	170.5	—	170.5
Exemplar acquisition	14.0	—	14.0
SkinMedica acquisition adjustments	17.3	—	17.3
Foreign exchange translation effects and other	(4.1) 2.5	(1.6)
Balance at September 30, 2013	\$ 497.5	\$ 1,836.5	\$ 2,334.0

The SkinMedica acquisition adjustments primarily relate to adjusting the assigned fair values associated with deferred tax assets and deferred tax liabilities and a contractual purchase price adjustment of \$2.8 million. The Company does not consider the adjustments to be material.

Note 6: Inventories

Components of inventories were:

	September 30, 2013	December 31, 2012
	(in millions)	
Finished products	\$ 182.6	\$ 179.9
Work in process	37.4	41.3
Raw materials	60.0	51.1
Total	\$ 280.0	\$ 272.3

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

At September 30, 2013 and December 31, 2012, approximately \$11.2 million and \$9.9 million, respectively, of the Company's finished goods inventories, primarily breast implants, were held on consignment at a large number of doctors' offices, clinics and hospitals worldwide. The value and quantity at any one location are not significant.

Note 7: Long-Term Debt

On March 12, 2013, the Company issued concurrently in a registered offering \$250.0 million in aggregate principal amount of 1.35% Senior Notes due 2018 (2018 Notes) and \$350.0 million in aggregate principal amount of 2.80% Senior Notes due 2023 (2023 Notes).

The 2018 Notes, which were sold at 99.793% of par value with an effective interest rate of 1.39%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 1.35% per annum, and are redeemable at any time at the Company's option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2018 Notes will be due and payable on March 15, 2018, unless earlier redeemed by the Company. The original discount of approximately \$0.5 million and the deferred debt issuance costs associated with the 2018 Notes are being amortized using the effective interest method over the stated term of five years.

The 2023 Notes, which were sold at 99.714% of par value with an effective interest rate of 2.83%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 2.80% per annum, and are redeemable at any time at the Company's option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption, if the redemption occurs prior to December 15, 2022 (three months prior to the maturity of the 2023 Notes). If the redemption occurs on or after December 15, 2022, then such redemption is not subject to the make-whole provision. The aggregate outstanding principal amount of the 2023 Notes will be due and payable on March 15, 2023, unless earlier redeemed by the Company. The original discount of approximately \$1.0 million and the deferred debt issuance costs associated with the 2023 Notes are being amortized using the effective interest method over the stated term of 10 years.

Note 8: Income Taxes

The provision for income taxes is determined using an estimated annual effective tax rate, which is generally less than the U.S. federal statutory rate, primarily because of lower tax rates in certain non-U.S. jurisdictions, R&D tax credits available in the United States, California, and other foreign jurisdictions and deductions available in the United States for domestic production activities. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as the mix of pre-tax earnings in the various tax jurisdictions in which the Company operates, valuation allowances against deferred tax assets, the recognition or derecognition of tax benefits related to uncertain tax positions, expected utilization of R&D tax credits and acquired net operating losses, and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. The American Taxpayer Relief Act of 2012 was enacted on January 2, 2013 and retroactively reinstated the U.S. R&D tax credit to January 1, 2012. In fiscal year 2013, the Company has recognized a retroactive benefit of \$15.4 million for the U.S. R&D tax credit for fiscal year 2012. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities along with net operating loss and tax credit carryovers.

The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was \$24.3 million and \$22.6 million as of September 30, 2013 and December 31, 2012, respectively.

Edgar Filing: ALLERGAN INC - Form 10-Q

The total amount of unrecognized tax benefits was \$58.1 million and \$61.9 million as of September 30, 2013 and December 31, 2012, respectively. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate was \$51.6 million and \$55.2 million as of September 30, 2013 and December 31, 2012, respectively. The Company expects that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities will decrease by approximately \$5.0 million to \$6.0 million due to the settlement of income tax audits, Appeals proceedings and Competent Authority negotiations in the United States and certain foreign jurisdictions.

Total interest accrued related to uncertain tax positions included in the Company's unaudited condensed consolidated balance sheets was \$10.7 million and \$10.0 million as of September 30, 2013 and December 31, 2012, respectively.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company has not provided for withholding and U.S. taxes for the unremitted earnings of certain non-U.S. subsidiaries because it has currently reinvested these earnings indefinitely in these foreign operations. At December 31, 2012, the Company had approximately \$3,083.5 million in unremitted earnings outside the United States for which withholding and U.S. taxes were not provided. Income tax expense would be incurred if these earnings were remitted to the United States. It is not practicable to estimate the amount of the deferred tax liability on such unremitted earnings. Upon remittance, certain foreign countries impose withholding taxes that are then available, subject to certain limitations, for use as credits against the Company's U.S. tax liability, if any. The Company annually updates its estimate of unremitted earnings outside the United States after the completion of each fiscal year.

Note 9: Share-Based Compensation

The Company recognizes compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at the grant date and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.

The fair value of stock option awards that vest based solely on a service condition is estimated using the Black-Scholes option-pricing model. The fair value of share-based awards that contain a market condition is generally estimated using a Monte Carlo simulation model, and the fair value of modifications to share-based awards is generally estimated using a lattice model.

The determination of fair value using the Black-Scholes, Monte Carlo simulation and lattice models is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. The Company currently estimates stock price volatility based upon an equal weighting of the historical average over the expected life of the award and the average implied volatility of at-the-money options traded in the open market. The Company estimates employee stock option exercise behavior based on actual historical exercise activity and assumptions regarding future exercise activity of unexercised, outstanding options.

Share-based compensation expense is recognized only for those awards that are ultimately expected to vest, and the Company has applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. Compensation expense for share-based awards based on a service condition is recognized using the straight-line single option method.

For the three and nine month periods ended September 30, 2013 and 2012, share-based compensation expense was as follows:

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Cost of sales	\$ 1.6	\$ 1.7	\$ 5.2	\$ 5.0
Selling, general and administrative	18.6	18.0	56.0	52.3
Research and development	7.1	6.5	21.9	20.6
Pre-tax share-based compensation expense	27.3	26.2	83.1	77.9
Income tax benefit	8.6	8.3	26.7	24.9
Net share-based compensation expense	\$ 18.7	\$ 17.9	\$ 56.4	\$ 53.0

As of September 30, 2013, total compensation cost related to non-vested stock options and restricted stock not yet recognized was approximately \$214.4 million, which is expected to be recognized over the next 46 months (32 months on a weighted-average basis). The Company has not capitalized as part of inventory any share-based compensation costs because such costs were negligible as of September 30, 2013.

Note 10: Employee Retirement and Other Benefit Plans

The Company sponsors various qualified defined benefit pension plans covering a substantial portion of its employees. In addition, the Company sponsors two supplemental nonqualified plans covering certain management employees and officers and one retiree health plan covering U.S. retirees and dependents.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Components of net periodic benefit cost for the three and nine month periods ended September 30, 2013 and 2012, respectively, were as follows:

	Three Months Ended			
	Pension Benefits		Other Postretirement Benefits	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
	(in millions)			
Service cost	\$7.1	\$ 6.4	\$0.4	\$ 0.4
Interest cost	11.5	10.8	0.5	0.5
Expected return on plan assets	(11.2)	(10.8)	—	—
Amortization of prior service costs	—	—	(0.7)	(0.7)
Recognized net actuarial losses	7.7	6.7	0.4	0.4
Net periodic benefit cost	\$15.1	\$ 13.1	\$0.6	\$ 0.6
	Nine Months Ended			
	Pension Benefits		Other Postretirement Benefits	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
	(in millions)			
Service cost	\$21.3	\$ 19.3	\$1.3	\$ 1.2
Interest cost	34.6	32.9	1.5	1.5
Expected return on plan assets	(33.7)	(32.6)	—	—
Amortization of prior service costs	—	—	(2.0)	(2.0)
Recognized net actuarial losses	23.2	20.2	1.1	1.0
Net periodic benefit cost	\$45.4	\$ 39.8	\$1.9	\$ 1.7

In 2013, the Company expects to pay contributions of between \$40.0 million and \$50.0 million for its U.S. and non-U.S. pension plans and between \$1.0 million and \$2.0 million for its other postretirement plan.

Note 11: Contingencies

Legal Proceedings

In the ordinary course of business, the Company is involved in various legal actions, government investigations and environmental proceedings, and we anticipate that additional actions will be brought against us in the future. The most significant of these actions, proceedings and investigations are described below. The following supplements and amends the discussion set forth in Note 12 "Commitments and Contingencies — Legal Proceedings" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and Note 11 "Contingencies — Legal Proceedings" in the Company's Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2013 and June 30, 2013 and is limited to certain recent developments concerning the Company's legal proceedings.

The Company's legal proceedings range from cases brought by a single plaintiff to a class action with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of the Company's business and a variety of claims (including but not limited to patent infringement, marketing, product liability, pricing and trade practices and securities law), some of which present novel factual allegations and/or unique legal theories. Complex legal proceedings frequently extend for several years, and a number of the matters pending against the Company are at very early stages of the legal process. As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable the Company to determine whether the proceeding is material to the Company or to estimate a range of possible loss, if

any. Unless otherwise disclosed, the Company is unable to estimate the possible loss or range of loss for the legal proceedings described below. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on the Company's consolidated results of operations, financial position or cash flows.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Patent Litigation

We are involved in patent litigation matters, including certain paragraph 4 invalidity and non-infringement claims brought under the Hatch-Waxman Act in the United States described below.

Zymar®.

In August 2013, the U.S. District Court for the District of Delaware entered judgment ruling that U.S. Patent Number 6,333,045 ('045 Patent) was invalid. In September 2013, the Company, with Senju Pharmaceuticals Co., Ltd. (Senju) and Kyorin Pharmaceutical Co., Ltd. (Kyorin), filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit and a motion for injunction pending appeal, which motion was denied.

Zymaxid®.

In August 2013, the U.S. District Court for the District of Delaware entered judgment in favor of Lupin Limited (Lupin) and Hi-Tech Pharmaceutical Co., Inc. (Hi-Tech) ruling that the '045 patent was invalid. In September 2013, the Company, with Senju and Kyorin, filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit and a motion for injunction pending appeal, which motion was denied.

In October 2013, the U.S. District Court for the District of Delaware dismissed the complaint against Apotex, Inc. (Apotex) alleging infringement of the '045 patent, subject to the appeal pending in the U.S. Court of Appeals for the Federal Circuit involving the '045 patent and Lupin and Hi-Tech.

In September 2013, Strides, Inc. and Agila Specialties Private Limited filed a motion to dismiss based upon the U.S. District Court for the District of Delaware's judgment in favor of Lupin and Hi-Tech ruling that the '045 patent was invalid and for lack of subject matter jurisdiction.

Combigan®.

In September and October 2013, Sandoz, Inc., Alcon Research, Ltd, and Apotex filed a motion seeking to modify the permanent injunction issued by the U.S. District Court for the Eastern District of Texas.

Other Litigation

Allergan, Inc. v. Cayman Chemical Company, et al. In October 2013, the U.S. Court of Appeals for the Federal Circuit heard oral argument on Athena Cosmetics Inc.'s appeal and took the matter under submission.

Contingencies

In 2009, the Company established a reserve for a contingent liability associated with regulation changes resulting from a final rule issued by the U.S. Department of Defense (DoD) that placed retroactive and prospective pricing limits on certain branded pharmaceuticals under the TRICARE Retail Pharmacy Program, even though such branded pharmaceuticals have not historically been subject to a contract with the Company. As of December 31, 2012, the reserve for the contingent liability was \$21.7 million and was included in "Other accrued expenses." In January 2013, the United States Court of Appeals for the District of Columbia Circuit affirmed an earlier decision by the United States District Court for the District of Columbia in favor of the DoD, and the Company subsequently paid all outstanding contingent TRICARE Retail Pharmacy Program claims.

As of June 1, 2012 the Company is largely self-insured for future product liability losses related to all of its products. Future product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The Company accrues for certain potential product liability losses estimated to be incurred, but not reported, to the extent they can be reasonably estimated. The Company estimates these accruals for potential losses based primarily on historical claims experience and data regarding product usage. The total value of self-insured product liability claims settled in the third quarter and the first nine months of 2013 and 2012, respectively, and the value of known and reasonably estimable incurred but unreported self-insured product liability claims pending as of September 30, 2013 are not material.

The Company has provided reserves for contingencies related to various lawsuits, claims and contractual disputes that management believes are probable and reasonably estimable. The amounts reserved for these contingencies as of September 30, 2013 are not material.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Note 12: Guarantees

The Company's Amended and Restated Certificate of Incorporation provides that the Company will indemnify, to the fullest extent permitted by the Delaware General Corporation Law, each person that is involved in or is, or is threatened to be, made a party to any action, suit or proceeding by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer of the Company or was serving at the request of the Company as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise. The Company has also entered into contractual indemnity agreements with each of its directors and executive officers pursuant to which, among other things, the Company has agreed to indemnify such directors and executive officers against any payments they are required to make as a result of a claim brought against such executive officer or director in such capacity, excluding claims (i) relating to the action or inaction of a director or executive officer that resulted in such director or executive officer gaining illegal personal profit or advantage, (ii) for an accounting of profits made from the purchase or sale of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of any state law or (iii) that are based upon or arise out of such director's or executive officer's knowingly fraudulent, deliberately dishonest or willful misconduct. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors' and officers' liability insurance policies intended to reduce the Company's monetary exposure and to enable the Company to recover a portion of any future amounts paid. The Company has not previously paid any material amounts to defend lawsuits or settle claims as a result of these indemnification provisions, but makes no assurance that such amounts will not be paid in the future. The Company currently believes the estimated fair value of these indemnification arrangements is minimal.

The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trials investigators in its drug, biologics and medical device development programs, in sponsored research agreements with academic and not-for-profit institutions, in various comparable agreements involving parties performing services for the Company in the ordinary course of business, and in its real estate leases. The Company also customarily agrees to certain indemnification provisions in its acquisition agreements and discovery and development collaboration agreements. With respect to the Company's clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator's institution relating to personal injury or property damage, violations of law or certain breaches of the Company's contractual obligations arising out of the research or clinical testing of the Company's products, compounds or drug candidates. With respect to real estate lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company's contractual obligations. The indemnification provisions appearing in the Company's acquisition agreements and collaboration agreements are similar, but in addition often provide indemnification for the collaborator in the event of third party claims alleging infringement of intellectual property rights. In each of the above cases, the terms of these indemnification provisions generally survive the termination of the agreement. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability intended to reduce the Company's exposure for indemnification and to enable the Company to recover a portion of any future amounts paid. The Company has not previously paid any material amounts to defend lawsuits or settle claims as a result of these indemnification provisions. As a result, the Company believes the estimated fair value of these indemnification arrangements is minimal.

Note 13: Product Warranties

The Company provides warranty programs for breast implant sales primarily in the United States, Europe and certain other countries. Management estimates the amount of potential future claims from these warranty programs based on actuarial analyses. Expected future obligations are determined based on the history of product shipments and claims and are discounted to a current value. The liability is included in both current and long-term liabilities in the Company's consolidated balance sheets. The U.S. programs include the ConfidencePlu® and ConfidencePlus® Premier warranty programs. The ConfidencePlus® program, which is limited to saline breast implants, currently provides lifetime product replacement, \$1,200 of financial assistance for surgical procedures within ten years of implantation and contralateral implant replacement. The ConfidencePlus® Premier program, which is standard for silicone gel implants and requires a low enrollment fee for saline breast implants, generally provides lifetime product replacement, \$2,400 of financial assistance for saline breast implants and \$3,500 of financial assistance for silicone gel breast implants for surgical procedures within ten years of implantation and contralateral implant replacement. The warranty programs in non-U.S. markets have similar terms and conditions to the U.S. programs. The Company does not warrant any level of aesthetic result and, as required by government regulation, makes extensive disclosures concerning the risks of the use of its products and breast implant surgery. Changes to actual warranty claims incurred and interest rates could have a material impact

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

on the actuarial analysis and the Company's estimated liabilities. A large majority of the product warranty liability arises from the U.S. warranty programs. The Company does not currently offer any similar warranty program on any other product.

The following table provides a reconciliation of the change in estimated product warranty liabilities through September 30, 2013:

	(in millions)
Balance at December 31, 2012	\$ 34.4
Provision for warranties issued during the period	5.8
Settlements made during the period	(5.4)
Decreases in warranty estimates	(0.7)
Balance at September 30, 2013	\$ 34.1
Current portion	\$ 7.5
Non-current portion	26.6
Total	\$ 34.1

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Note 14: Earnings Per Share

The table below presents the computation of basic and diluted earnings per share:

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions, except per share amounts)			
Net earnings attributable to Allergan, Inc.:				
Earnings from continuing operations attributable to Allergan, Inc.:				
Earnings from continuing operations	\$ 332.9	\$ 252.9	\$ 959.9	\$ 778.4
Less net earnings attributable to noncontrolling interest	1.0	1.2	4.2	2.7
Earnings from continuing operations attributable to Allergan, Inc.	331.9	251.7	955.7	775.7
Loss from discontinued operations	(32.1) (2.3) (283.5) (1.1
Net earnings attributable to Allergan, Inc.	\$ 299.8	\$ 249.4	\$ 672.2	\$ 774.6
Weighted average number of shares outstanding				
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price	296.5	300.1	296.7	302.1
Diluted shares	300.7	305.3	301.9	307.7
Basic earnings per share attributable to Allergan, Inc. stockholders:				
Continuing operations	\$ 1.12	\$ 0.84	\$ 3.22	\$ 2.57
Discontinued operations	(0.11) (0.01) (0.95) (0.01
Net basic earnings per share attributable to Allergan, Inc. stockholders	\$ 1.01	\$ 0.83	\$ 2.27	\$ 2.56
Diluted earnings per share attributable to Allergan, Inc. stockholders:				
Continuing operations	\$ 1.10	\$ 0.82	\$ 3.17	\$ 2.52
Discontinued operations	(0.10) —	(0.94) —
Net diluted earnings per share attributable to Allergan, Inc. stockholders	\$ 1.00	\$ 0.82	\$ 2.23	\$ 2.52

For the three and nine month periods ended September 30, 2013, options to purchase 8.1 million and 5.6 million shares of common stock at exercise prices ranging from \$84.40 to \$113.55 per share, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect from the assumed exercise of these options calculated under the treasury stock method would be anti-dilutive.

For the three and nine month periods ended September 30, 2012, options to purchase 4.5 million and 5.9 million shares of common stock at exercise prices ranging from \$76.98 to \$92.90 and \$75.58 to \$92.90 per share, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect from the assumed exercise of these options calculated under the treasury stock method would be anti-dilutive.

Note 15: Financial Instruments

In the normal course of business, operations of the Company are exposed to risks associated with fluctuations in interest rates and foreign currency exchange rates. The Company addresses these risks through controlled risk management that includes

21

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

the use of derivative financial instruments to economically hedge or reduce these exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes.

The Company has not experienced any losses to date on its derivative financial instruments due to counterparty credit risk.

To ensure the adequacy and effectiveness of its interest rate and foreign exchange hedge positions, the Company continually monitors its interest rate swap positions and foreign exchange forward and option positions both on a stand-alone basis and in conjunction with its underlying interest rate and foreign currency exposures, from an accounting and economic perspective.

However, given the inherent limitations of forecasting and the anticipatory nature of the exposures intended to be hedged, the Company cannot assure that such programs will offset more than a portion of the adverse financial impact resulting from unfavorable movements in either interest or foreign exchange rates. In addition, the timing of the accounting for recognition of gains and losses related to mark-to-market instruments for any given period may not coincide with the timing of gains and losses related to the underlying economic exposures and, therefore, may adversely affect the Company's consolidated operating results and financial position.

Interest Rate Risk Management

The Company's interest income and expense are more sensitive to fluctuations in the general level of U.S. interest rates than to changes in rates in other markets. Changes in U.S. interest rates affect the interest earned on cash and equivalents and short-term investments and interest expense on debt, as well as costs associated with foreign currency contracts.

On January 31, 2007, the Company entered into a nine-year, two month interest rate swap with a \$300.0 million notional amount. The swap received interest at a fixed rate of 5.75% and paid interest at a variable interest rate equal to 3-month LIBOR plus 0.368%, and effectively converted \$300.0 million of the Company's \$800.0 million in aggregate principal amount of 5.75% Senior Notes due 2016 (2016 Notes) to a variable interest rate. Based on the structure of the hedging relationship, the hedge met the criteria for using the short-cut method for a fair value hedge. In September 2012, the Company terminated the interest rate swap and received \$54.7 million, which included accrued interest of \$3.7 million. Upon termination of the interest rate swap, the Company added the net fair value received of \$51.0 million to the carrying value of the 2016 Notes. The amount received for the termination of the interest rate swap is being amortized as a reduction to interest expense over the remaining life of the debt, which effectively fixes the interest rate for the remaining term of the 2016 Notes at 3.94%. During the three and nine month periods ended September 30, 2013, the Company recognized \$3.3 million and \$9.8 million, respectively, as a reduction of interest expense due to the effect of the interest rate swap. During the three and nine month periods ended September 30, 2012, the Company recognized \$3.2 million and \$10.6 million, respectively, as a reduction of interest expense due to the effect of the interest rate swap.

In February 2006, the Company entered into interest rate swap contracts based on 3-month LIBOR with an aggregate notional amount of \$800.0 million, a swap period of 10 years and a starting swap rate of 5.198%. The Company entered into these swap contracts as a cash flow hedge to effectively fix the future interest rate for the 2016 Notes. In April 2006, the Company terminated the interest rate swap contracts and received approximately \$13.0 million. The total gain was recorded to accumulated other comprehensive loss and is being amortized as a reduction to interest expense over a 10 year period to match the term of the 2016 Notes. During the three and nine month periods ended September 30, 2013 and 2012, the Company recognized \$0.3 million and \$1.0 million, respectively, as a reduction of interest expense due to the amortization of deferred holding gains on derivatives designated as cash flow hedges. These amounts were reclassified from accumulated other comprehensive loss. As of September 30, 2013, the remaining unrecognized gain of \$3.3 million (\$2.0 million, net of tax) is recorded as a component of accumulated other comprehensive loss. The Company expects to reclassify an estimated pre-tax amount of \$1.3 million from accumulated other comprehensive loss as a reduction in interest expense during fiscal year 2013 due to the amortization of deferred holding gains on derivatives designated as cash flow hedges.

Foreign Exchange Risk Management

Overall, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company's consolidated revenues or operating costs and expenses as expressed in U.S. dollars.

From time to time, the Company enters into foreign currency option and forward contracts to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on its core business issues. Accordingly, the Company enters into various contracts which change in value as foreign exchange rates change to economically

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

offset the effect of changes in the value of foreign currency assets and liabilities, commitments and anticipated foreign currency denominated sales and operating expenses. The Company enters into foreign currency option and forward contracts in amounts between minimum and maximum anticipated foreign exchange exposures, generally for periods not to exceed 18 months. The Company does not designate these derivative instruments as accounting hedges.

The Company uses foreign currency option contracts, which provide for the sale or purchase of foreign currencies, to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of the Company's business. Probable but not firmly committed transactions are comprised primarily of sales of products and purchases of raw material in currencies other than the U.S. dollar. The foreign currency option contracts are entered into to reduce the volatility of earnings generated in currencies other than the U.S. dollar. While these instruments are subject to fluctuations in value, such fluctuations are anticipated to offset changes in the value of the underlying exposures.

Changes in the fair value of open foreign currency option contracts and any realized gains (losses) on settled contracts are recorded through earnings as "Other, net" in the accompanying unaudited condensed consolidated statements of earnings. During the three and nine month periods ended September 30, 2013, the Company recognized realized gains on settled foreign currency option contracts of \$2.3 million and \$3.9 million, respectively, and net unrealized (losses) gains on open foreign currency option contracts of \$(7.6) million and \$4.3 million, respectively. During the three and nine month periods ended September 30, 2012, the Company recognized realized gains on settled foreign currency option contracts of \$3.8 million and \$10.8 million, respectively, and net unrealized losses on open foreign currency option contracts of \$7.1 million and \$15.2 million, respectively. The premium costs of purchased foreign exchange option contracts are recorded in "Other current assets" and amortized to "Other, net" over the life of the options.

All of the Company's outstanding foreign exchange forward contracts are entered into to offset the change in value of certain intercompany receivables or payables that are subject to fluctuations in foreign currency exchange rates. The realized and unrealized gains and losses from foreign currency forward contracts and the revaluation of the foreign denominated intercompany receivables or payables are recorded through "Other, net" in the accompanying unaudited condensed consolidated statements of earnings. During the three and nine month periods ended September 30, 2013, the Company recognized total realized and unrealized gains from foreign exchange forward contracts of \$0.3 million and \$3.5 million, respectively. During the three and nine month periods ended September 30, 2012, the Company recognized total realized and unrealized losses from foreign exchange forward contracts of \$0.7 million and \$1.9 million, respectively.

The fair value of outstanding foreign exchange option and forward contracts, collectively referred to as foreign currency derivative financial instruments, are recorded in "Other current assets" and "Accounts payable." At September 30, 2013 and December 31, 2012, foreign currency derivative assets associated with the foreign exchange option contracts of \$10.9 million and \$9.9 million, respectively, were included in "Other current assets." At September 30, 2013 and December 31, 2012, net foreign currency derivative assets associated with the foreign exchange forward contracts of \$0.4 million and \$0.3 million, respectively, were included in "Other current assets." At September 30, 2013 and December 31, 2012, the notional principal and fair value of the Company's outstanding foreign currency derivative financial instruments were as follows:

	September 30, 2013		December 31, 2012	
	Notional Principal	Fair Value	Notional Principal	Fair Value
Foreign currency forward exchange contracts (Receive U.S. dollar/pay foreign currency)	\$46.2	\$(0.1)	\$44.6	\$0.3
Foreign currency forward exchange contracts (Pay U.S. dollar/receive foreign currency)	40.1	0.5	39.6	—
Foreign currency sold — put options	407.0	10.9	501.6	9.9

The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2013 and December 31, 2012, and do not represent the amount of the Company's exposure to market loss. The estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information as of September 30, 2013 and December 31, 2012. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Other Financial Instruments

At September 30, 2013 and December 31, 2012, the Company's other financial instruments included cash and equivalents, short-term investments, trade receivables, non-marketable equity investments, accounts payable and borrowings. The carrying amount of cash and equivalents, short-term investments, trade receivables and accounts payable approximates fair value due to the short-term maturities of these instruments. The fair value of non-marketable equity investments, which represent investments in start-up technology companies, are estimated based on information provided by these companies. The fair value of notes payable and long-term debt are estimated based on quoted market prices and interest rates.

The carrying amount and estimated fair value of the Company's other financial instruments at September 30, 2013 and December 31, 2012 were as follows:

	September 30, 2013		December 31, 2012	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	(in millions)			
Cash and equivalents	\$2,686.3	\$2,686.3	\$2,701.8	\$2,701.8
Short-term investments	524.6	524.6	260.6	260.6
Non-current non-marketable equity investments	6.1	6.1	9.0	9.0
Notes payable	37.2	37.2	48.8	48.8
Long-term debt	2,101.5	2,181.4	1,512.4	1,673.0

In the first quarter of 2013, the Company recorded an impairment charge of \$3.7 million due to the other than temporary decline in value of a non-marketable equity investment.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk principally consist of trade receivables. Wholesale distributors, major retail chains and managed care organizations account for a substantial portion of trade receivables. This risk is limited due to the number of customers comprising the Company's customer base, and their geographic dispersion. At September 30, 2013, no single customer represented more than 10% of trade receivables, net. Ongoing credit evaluations of customers' financial condition are performed and, generally, no collateral is required. The Company has purchased an insurance policy intended to reduce the Company's exposure to potential credit risks associated with certain U.S. customers. To date, no claims have been made against the insurance policy. The Company maintains reserves for potential credit losses and such losses, in the aggregate, have not historically exceeded management's estimates.

Note 16: Fair Value Measurements

The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

As of September 30, 2013 and December 31, 2012, the Company has certain assets and liabilities that are required to be measured at fair value on a recurring basis. These include cash equivalents, short-term investments, foreign exchange derivatives, deferred executive compensation investments and liabilities and contingent consideration liabilities. These assets and liabilities are classified in the table below in one of the three categories of the fair value hierarchy described above.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

	September 30, 2013			
	Total (in millions)	Level 1	Level 2	Level 3
Assets				
Commercial paper	\$1,641.2	\$—	\$1,641.2	\$—
Foreign time deposits	312.9	—	312.9	—
Other cash equivalents	1,022.6	—	1,022.6	—
Foreign exchange derivative assets	11.3	—	11.3	—
Deferred executive compensation investments	93.0	74.2	18.8	—
	\$3,081.0	\$74.2	\$3,006.8	\$—
Liabilities				
Deferred executive compensation liabilities	\$85.2	\$66.4	\$18.8	\$—
Contingent consideration liabilities	212.5	—	—	212.5
	\$297.7	\$66.4	\$18.8	\$212.5
	December 31, 2012			
	Total (in millions)	Level 1	Level 2	Level 3
Assets				
Commercial paper	\$1,709.0	\$—	\$1,709.0	\$—
Foreign time deposits	341.7	—	341.7	—
Other cash equivalents	685.0	—	685.0	—
Foreign exchange derivative assets	10.2	—	10.2	—
Deferred executive compensation investments	81.7	66.8	14.9	—
	\$2,827.6	\$66.8	\$2,760.8	\$—
Liabilities				
Deferred executive compensation liabilities	\$73.5	\$58.6	\$14.9	\$—
Contingent consideration liabilities	224.3	—	—	224.3
	\$297.8	\$58.6	\$14.9	\$224.3

Cash equivalents consist of commercial paper, foreign time deposits and other cash equivalents. Other cash equivalents consist primarily of money-market fund investments. Short-term investments consist of commercial paper. Cash equivalents and short-term investments are valued at cost, which approximates fair value due to the short-term maturities of these instruments. Foreign currency derivative assets and liabilities are valued using quoted forward foreign exchange prices and option volatility at the reporting date. The Company believes the fair values assigned to its derivative instruments as of September 30, 2013 and December 31, 2012 are based upon reasonable estimates and assumptions. Assets and liabilities related to deferred executive compensation consist of actively traded mutual funds classified as Level 1 and money-market funds classified as Level 2.

Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. The ultimate amount of future payments is based on specified future criteria, such as sales performance and the achievement of certain future development, regulatory and sales milestones and other contractual performance conditions. The Company evaluates its estimates of the fair value of contingent consideration liabilities on a periodic basis. Any changes in the fair value of contingent consideration liabilities are recorded as SG&A expense.

The Company estimates the fair value of the contingent consideration liabilities related to sales performance using the income approach, which involves forecasting estimated future net cash flows and discounting the net cash flows to their present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent

consideration liabilities related to the achievement of future development and regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The Company

25

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

estimates the fair value of the contingent consideration liabilities associated with sales milestones by employing Monte Carlo simulations to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate. The fair value of other contractual performance conditions is measured by assigning an achievement probability to each payment and discounting the payment to its present value using the Company's estimated cost of borrowing. The unobservable inputs to the valuation models that have the most significant effect on the fair value of the Company's contingent consideration liabilities are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA. The Company currently estimates that the probabilities of success in meeting the specified development milestones are between 40% and 75%. The following table provides a reconciliation of the change in the contingent consideration liabilities through September 30, 2013:

	(in millions)
Balance at December 31, 2012	\$224.3
Change in the estimated fair value of the contingent consideration liabilities	4.8
Payments made during the period	(11.1)
Foreign exchange translation effects	(5.5)
Balance at September 30, 2013	\$212.5

Note 17: Business Segment Information

The Company operates its business on the basis of two reportable segments — specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a broad range of pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox® for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and physician-dispensed skin care products; and urologics products. The medical devices segment produces a broad range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company provides global marketing strategy teams to ensure development and execution of a consistent marketing strategy for its products in all geographic regions that share similar distribution channels and customers.

The Company evaluates segment performance on a product net sales and operating income basis exclusive of general and administrative expenses and other indirect costs, legal settlement expenses, impairment of intangible assets and related costs, restructuring charges, amortization of certain identifiable intangible assets related to business combinations, asset acquisitions and related capitalized licensing costs and certain other adjustments, which are not allocated to the Company's segments for performance assessment by the Company's chief operating decision maker. Other adjustments excluded from the Company's segments for performance assessment represent income or expenses that do not reflect, according to established Company-defined criteria, operating income or expenses associated with the Company's core business activities. Because operating segments are generally defined by the products they design and sell, they do not make sales to each other. The Company does not discretely allocate assets to its operating segments, nor does the Company's chief operating decision maker evaluate operating segments using discrete asset information.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Operating Segments

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
	(in millions)			
Product net sales:				
Specialty pharmaceuticals	\$ 1,329.8	\$ 1,178.5	\$ 3,909.3	\$ 3,530.6
Medical devices	198.6	175.2	628.6	570.9
Total product net sales	1,528.4	1,353.7	4,537.9	4,101.5
Other revenues	30.3	22.8	78.1	73.0
Total revenues	\$ 1,558.7	\$ 1,376.5	\$ 4,616.0	\$ 4,174.5
Operating income:				
Specialty pharmaceuticals	\$ 593.4	\$ 503.4	\$ 1,652.8	\$ 1,449.8
Medical devices	58.5	49.6	188.2	169.4
Total segments	651.9	553.0	1,841.0	1,619.2
General and administrative expenses, other indirect costs and other adjustments	133.4	177.9	401.2	418.9
Amortization of intangible assets (a)	27.7	17.0	80.4	49.5
Restructuring charges	0.6	0.6	4.9	1.5
Total operating income	\$ 490.2	\$ 357.5	\$ 1,354.5	\$ 1,149.3

(a) Represents amortization of certain identifiable intangible assets related to business combinations, asset acquisitions and related capitalized licensing costs, as applicable.

Product net sales for the Company's various global product portfolios are presented below. The Company's principal geographic markets are the United States, Europe, Latin America and Asia Pacific. The U.S. information is presented separately as it is the Company's headquarters country. U.S. sales represented 62.5% and 62.1% of the Company's total consolidated product net sales for the three month periods ended September 30, 2013 and 2012, respectively. U.S. sales represented 61.5% and 60.8% of the Company's total consolidated product net sales for the nine month periods ended September 30, 2013 and 2012, respectively.

Sales to two customers in the Company's specialty pharmaceuticals segment each generated over 10% of the Company's total consolidated product net sales. Sales to McKesson Drug Company for the three month periods ended September 30, 2013 and 2012 were 16.0% and 14.1%, respectively, of the Company's total consolidated product net sales, and 14.8% and 15.0%, respectively, of the Company's total consolidated product net sales for the nine month periods ended September 30, 2013 and 2012. Sales to Cardinal Health, Inc. for the three month periods ended September 30, 2013 and 2012 were 13.7% and 16.3%, respectively, of the Company's total consolidated product net sales, and 14.1% and 14.8%, respectively, of the Company's total consolidated product net sales for the nine month periods ended September 30, 2013 and 2012. No other country or single customer generates over 10% of the Company's total consolidated product net sales. Net sales for the Europe region also include sales to customers in Africa and the Middle East, and net sales in the Asia Pacific region include sales to customers in Australia and New Zealand.

Table of Contents

ALLERGAN, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Product Net Sales by Product Line

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Specialty Pharmaceuticals:				
Eye Care Pharmaceuticals	\$717.1	\$ 663.2	\$2,108.1	\$ 1,986.1
Botox®/Neuromodulators	485.7	431.6	1,456.6	1,291.7
Skin Care and Other	127.0	83.7	344.6	252.8
Total Specialty Pharmaceuticals	1,329.8	1,178.5	3,909.3	3,530.6
Medical Devices:				
Breast Aesthetics	91.9	86.1	288.3	285.7
Facial Aesthetics	106.7	89.1	340.3	285.2
Total Medical Devices	198.6	175.2	628.6	570.9
Total product net sales	\$1,528.4	\$ 1,353.7	\$4,537.9	\$ 4,101.5

Geographic Information

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Product net sales:				
United States	\$955.6	\$ 840.0	\$2,791.9	\$ 2,494.1
Europe	282.6	246.5	909.5	816.5
Latin America	104.6	93.6	286.5	282.7
Asia Pacific	117.8	109.7	348.7	318.6
Other	67.8	63.9	201.3	189.6
Total product net sales	\$1,528.4	\$ 1,353.7	\$4,537.9	\$ 4,101.5
			September 30,	December 31,
			2013	2012
			(in millions)	

Long-lived assets:

United States	\$4,289.2	\$ 3,242.9
Europe	545.2	538.6
Latin America	51.2	55.2
Asia Pacific	51.5	53.8
Other	1.5	2.2
Total long-lived assets	\$4,938.6	\$ 3,892.7

The increase in long-lived assets located in the United States at September 30, 2013 compared to December 31, 2012 is primarily due to an increase in intangible assets and goodwill related to the acquisitions of MAP completed in the first quarter of 2013 and Exemplar completed in the second quarter of 2013.

Table of Contents

ALLERGAN, INC.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This financial review presents our operating results for the three and nine month periods ended September 30, 2013 and 2012, and our financial condition at September 30, 2013. The following discussion contains forward-looking statements which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. We discuss such risks, uncertainties and other factors throughout this report and specifically under the caption “Risk Factors” in Part II, Item 1A below. The following review should be read in connection with the information presented in our unaudited condensed consolidated financial statements and related notes for the three and nine month periods ended September 30, 2013 included in this report and our audited consolidated financial statements and related notes for the year ended December 31, 2012 included in our 2012 Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.

Critical Accounting Policies, Estimates and Assumptions

The preparation and presentation of financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to establish policies and to make estimates and assumptions that affect the amounts reported in our consolidated financial statements. In our judgment, the accounting policies, estimates and assumptions described below have the greatest potential impact on our consolidated financial statements. Accounting assumptions and estimates are inherently uncertain and actual results may differ materially from our estimates.

Revenue Recognition

We recognize revenue from product sales when goods are shipped and title and risk of loss transfer to our customers. A substantial portion of our revenue is generated by the sale of specialty pharmaceutical products (primarily eye care pharmaceuticals and skin care and other products) to wholesalers within the United States, and we have a policy to attempt to maintain average U.S. wholesaler inventory levels at an amount less than eight weeks of our net sales. A portion of our revenue is generated from consigned inventory of breast implants maintained at physician, hospital and clinic locations. These customers are contractually obligated to maintain a specific level of inventory and to notify us upon the use of consigned inventory. Revenue for consigned inventory is recognized at the time we are notified by the customer that the product has been used. Notification is usually through the replenishing of the inventory, and we periodically review consignment inventories to confirm the accuracy of customer reporting.

We generally offer cash discounts to customers for the early payment of receivables. Those discounts are recorded as a reduction of revenue and accounts receivable in the same period that the related sale is recorded. The amounts reserved for cash discounts were \$6.2 million and \$4.2 million at September 30, 2013 and December 31, 2012, respectively. Provisions for cash discounts deducted from consolidated sales in the third quarter of 2013 and 2012 were \$19.3 million and \$17.6 million, respectively. Provisions for cash discounts deducted from consolidated sales in the first nine months of 2013 and 2012 were \$55.6 million and \$51.4 million, respectively.

We permit returns of product from most product lines by any class of customer if such product is returned in a timely manner, in good condition and from normal distribution channels. Return policies in certain international markets and for certain medical device products, primarily breast implants, provide for more stringent guidelines in accordance with the terms of contractual agreements with customers. Our estimates for sales returns are based upon the historical patterns of product returns matched against sales, and management’s evaluation of specific factors that may increase the risk of product returns. The amount of allowances for sales returns recognized in our consolidated balance sheets at September 30, 2013 and December 31, 2012 were \$84.6 million and \$77.9 million, respectively, and are recorded in “Other accrued expenses” and “Trade receivables, net” in our consolidated balance sheets. Provisions for sales returns deducted from consolidated sales were \$113.8 million and \$91.8 million in the third quarter of 2013 and 2012, respectively. Provisions for sales returns deducted from consolidated sales were \$330.7 million and \$300.8 million in the first nine months of 2013 and 2012, respectively. The increases in the amount of allowances for sales returns at September 30, 2013 compared to December 31, 2012 and the provisions for sales returns in the third quarter and the first nine months of 2013 compared to the third quarter and the first nine months of 2012 are primarily due to increased overall product sales volume and an increase in estimated product sales return rates for our breast aesthetics

products, partially offset by a slight decrease in estimated product sales return rates for our skin care and other products. Actual historical allowances for cash discounts and product returns have been consistent with the amounts reserved or accrued.

We participate in various U.S. federal and state government rebate programs, the largest of which are Medicaid, Medicare and the U.S. Department of Veterans Affairs. We also have contracts with various managed care and group purchasing organizations that provide for sales rebates and other contractual discounts. In the United States, we also incur chargebacks, which are reimbursements to wholesalers for honoring contracted prices to third parties. Outside of the United States, we incur sales allowances based on contractual provisions and legislative mandates. We also offer rebate and other incentive programs directly to our customers

Table of Contents

for our aesthetic products and certain therapeutic products, including Botox[®] Cosmetic, Juvéderm[®], Latisse[®], Natrelle[®], Acuvail[®], Aczone[®], Sanctura XR[®] and Restasis[®], and for certain other skin care products. Sales rebates and incentive accruals reduce revenue in the same period that the related sale is recorded and are included in “Other accrued expenses” in our consolidated balance sheets. The amounts accrued for sales rebates and other incentive programs were \$278.7 million and \$269.6 million at September 30, 2013 and December 31, 2012, respectively. Provisions for sales rebates and other incentive programs deducted from consolidated sales were \$292.2 million in the third quarter of 2013 compared to \$241.6 million in the third quarter of 2012. The \$50.6 million increase in the provisions for sales rebates and other incentive programs in the third quarter of 2013 is due to a \$22.8 million increase in provisions for rebates associated with U.S. federal and state government programs, a \$0.3 million increase in managed health care rebates and other contractual discounts, a \$10.8 million increase in chargebacks, a \$7.7 million increase in sales allowances outside of the United States and a \$9.0 million increase in provisions for consumer coupons and other customer incentives. Provisions for sales rebates and other incentive programs deducted from consolidated sales were \$831.1 million for the first nine months of 2013 compared to \$708.6 million for the first nine months of 2012. The \$122.5 million increase in the provisions for sales rebates and other incentive programs in the first nine months of 2013 is due to a \$50.4 million increase in provisions for rebates associated with U.S. federal and state government programs, a \$13.3 million increase in managed health care rebates and other contractual discounts, a \$14.8 million increase in chargebacks, an \$18.6 million increase in sales allowances outside of the United States and a \$25.4 million increase in provisions for consumer coupons and other customer incentives. The increase in provisions for sales rebates and other incentive programs in the three and nine month periods ended September 30, 2013 compared to the respective periods in 2012 is primarily due to increased eye care pharmaceutical sales in the United States and a shift in U.S. patient populations to government reimbursed programs, which typically have higher rebate percentages than other managed care programs. Rebates related to the Medicare Part D coverage gap in the United States increased in the three and nine month periods ended September 30, 2013 compared to the respective periods in 2012, which we believe was primarily due to an increase in patients covered under employer group waiver plans. In addition, provisions for sales rebates and other incentive programs were negatively impacted by an increase in government rebates in Europe related to austerity measures, increased incentives offered directly to customers in the United States, and increases in our published list prices in the United States for pharmaceutical products, which occurred for several of our products in each of 2013 and 2012 and generally result in higher provisions for sales rebates and other incentive programs deducted from consolidated sales.

Our procedures for estimating amounts accrued for sales rebates and other incentive programs at the end of any period are based on available quantitative data and are supplemented by management’s judgment with respect to many factors, including but not limited to, current market dynamics, changes in contract terms, changes in sales trends, an evaluation of current laws and regulations and product pricing. Quantitatively, we use historical sales, product utilization and rebate data and apply forecasting techniques in order to estimate our liability amounts. Qualitatively, management’s judgment is applied to these items to modify, if appropriate, the estimated liability amounts. There are inherent risks in this process. For example, customers may not achieve assumed utilization levels; customers may misreport their utilization to us; actual utilization and reimbursement rates under government rebate programs may differ from those estimated; and actual movements of the U.S. Consumer Price Index for All Urban Consumers, or CPI-U, which affect our rebate programs with U.S. federal and state government agencies, may differ from those estimated. On a quarterly basis, adjustments to our estimated liabilities for sales rebates and other incentive programs related to sales made in prior periods have not been material and have generally been less than 0.5% of consolidated product net sales. An adjustment to our estimated liabilities of 0.5% of consolidated product net sales on a quarterly basis would result in an increase or decrease to net sales and earnings before income taxes of approximately \$7.0 million to \$8.0 million. The sensitivity of our estimates can vary by program and type of customer. Additionally, there is a significant time lag between the date we determine the estimated liability and when we actually pay the liability. Due to this time lag, we record adjustments to our estimated liabilities over several periods, which can result in a net increase to earnings or a net decrease to earnings in those periods. Material differences may result in the amount of revenue we recognize from product sales if the actual amount of rebates and incentives differ materially from the amounts estimated by management.

We recognize license fees, royalties and reimbursement income for services provided as other revenues based on the facts and circumstances of each contractual agreement. In general, we recognize income upon the signing of a contractual agreement that grants rights to products or technology to a third party if we have no further obligation to provide products or services to the third party after entering into the contract. We recognize contingent consideration earned from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. We defer income under contractual agreements when we have further obligations that indicate that a separate earnings process has not been completed.

Contingent Consideration

Contingent consideration liabilities represent future amounts we may be required to pay in conjunction with various business combinations. The ultimate amount of future payments is based on specified future criteria, such as sales performance and the achievement of certain future development, regulatory and sales milestones and other contractual performance conditions. We

Table of Contents

estimate the fair value of the contingent consideration liabilities related to sales performance using the income approach, which involves forecasting estimated future net cash flows and discounting the net cash flows to their present value using a risk-adjusted rate of return. We estimate the fair value of the contingent consideration liabilities related to the achievement of future development and regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. We estimate the fair value of the contingent consideration liabilities associated with sales milestones by employing Monte Carlo simulations to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate. The fair value of other contractual performance conditions is measured by assigning an achievement probability to each payment and discounting the payment to its present value using our estimated cost of borrowing. We evaluate our estimates of the fair value of contingent consideration liabilities on a periodic basis. Any changes in the fair value of contingent consideration liabilities are recorded through earnings as "Selling, general and administrative" in the accompanying unaudited condensed consolidated statements of earnings. The total estimated fair value of contingent consideration liabilities was \$212.5 million and \$224.3 million at September 30, 2013 and December 31, 2012, respectively, and was included in "Other accrued expenses" and "Other liabilities" in our consolidated balance sheets.

Pensions

We sponsor various pension plans in the United States and abroad in accordance with local laws and regulations. Our U.S. pension plans account for a large majority of our aggregate pension plans' net periodic benefit costs and projected benefit obligations. In connection with these plans, we use certain actuarial assumptions to determine the plans' net periodic benefit costs and projected benefit obligations, the most significant of which are the expected long-term rate of return on assets and the discount rate.

Our assumption for the weighted average expected long-term rate of return on assets in our U.S. funded pension plan for determining the net periodic benefit cost is 6.25% and 6.75% for 2013 and 2012, respectively. Our assumptions for the weighted average expected long-term rate of return on assets in our non-U.S. funded pension plans are 4.36% and 4.80% for 2013 and 2012, respectively. For our U.S. funded pension plan, we determine, based upon recommendations from our pension plan's investment advisors, the expected rate of return using a building block approach that considers diversification and rebalancing for a long-term portfolio of invested assets. Our investment advisors study historical market returns and preserve long-term historical relationships between equities and fixed income in a manner consistent with the widely-accepted capital market principle that assets with higher volatility generate a greater return over the long run. They also evaluate market factors such as inflation and interest rates before long-term capital market assumptions are determined. For our non-U.S. funded pension plans, the expected rate of return was determined based on asset distribution and assumed long-term rates of return on fixed income instruments and equities. Market conditions and other factors can vary over time and could significantly affect our estimates of the weighted average expected long-term rate of return on plan assets. The expected rate of return is applied to the market-related value of plan assets. As a sensitivity measure, the effect of a 0.25% decline in our rate of return on assets assumptions for our U.S. and non-U.S. funded pension plans would increase our expected 2013 pre-tax pension benefit cost by approximately \$2.0 million.

The weighted average discount rates used to calculate our U.S. and non-U.S. pension benefit obligations at December 31, 2012 were 4.23% and 4.55%, respectively. The weighted average discount rates used to calculate our U.S. and non-U.S. net periodic benefit costs for 2013 were 4.23% and 4.55%, respectively, and for 2012, 4.63% and 5.14%, respectively. We determine the discount rate based upon a hypothetical portfolio of high quality fixed income investments with maturities that mirror the pension benefit obligations at the plans' measurement date. Market conditions and other factors can vary over time and could significantly affect our estimates for the discount rates used to calculate our pension benefit obligations and net periodic benefit costs for future years. As a sensitivity measure, the effect of a 0.25% decline in the discount rate assumption for our U.S. and non-U.S. pension plans would increase our expected 2013 pre-tax pension benefit costs by approximately \$5.2 million and increase our pension plans' projected benefit obligations at December 31, 2012 by approximately \$50.6 million.

Share-Based Compensation

We recognize compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at the grant date and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.

The fair value of stock option awards that vest based on a service condition is estimated using the Black-Scholes option-pricing model. The fair value of share-based awards that contain a market condition is generally estimated using a Monte Carlo simulation model, and the fair value of modifications to share-based awards is generally estimated using a lattice model.

The determination of fair value using the Black-Scholes, Monte Carlo simulation and lattice models is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. We currently estimate stock

Table of Contents

price volatility based upon an equal weighting of the historical average over the expected life of the award and the average implied volatility of at-the-money options traded in the open market. We estimate employee stock option exercise behavior based on actual historical exercise activity and assumptions regarding future exercise activity of unexercised, outstanding options.

Share-based compensation expense is recognized only for those awards that are ultimately expected to vest, and we have applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. Compensation expense for share-based awards based on a service condition is recognized using the straight-line single option method.

Product Liability Self-Insurance

As of June 1, 2012, we are largely self-insured for future product liability losses related to all of our products. We have historically been and continue to be self-insured for any product liability losses related to our breast implant products. We maintain third party insurance coverage that we believe is adequate to cover potential product liability losses for injuries alleged to have occurred prior to June 1, 2011 related to Botox[®] and Botox[®] Cosmetic and prior to June 1, 2012 related to all of our other products. Future product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The factors to consider in developing product liability reserves include the merits and jurisdiction of each claim, the nature and the number of other similar current and past claims, the nature of the product use and the likelihood of settlement. In addition, we accrue for certain potential product liability losses estimated to be incurred, but not reported, to the extent they can be reasonably estimated. We estimate these accruals for potential losses based primarily on historical claims experience and data regarding product usage. The total value of self-insured product liability claims settled in the third quarter and the first nine months of 2013 and 2012, respectively, and the value of known and reasonably estimable incurred but unreported self-insured product liability claims pending as of September 30, 2013 are not expected to have a material effect on our results of operations or liquidity.

Income Taxes

The provision for income taxes is determined using an estimated annual effective tax rate, which is generally less than the U.S. federal statutory rate, primarily because of lower tax rates in certain non-U.S. jurisdictions, research and development, or R&D, tax credits available in the United States, California, and other foreign jurisdictions and deductions available in the United States for domestic production activities. Our effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as the mix of pre-tax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or derecognition of tax benefits related to uncertain tax positions, expected utilization of R&D tax credits and acquired net operating losses and changes in or the interpretation of tax laws in jurisdictions where we conduct business. The American Taxpayer Relief Act of 2012 was enacted on January 2, 2013 and retroactively reinstated the U.S. R&D tax credit to January 1, 2012. In fiscal year 2013, we have recognized a retroactive benefit of \$15.4 million for the U.S. R&D tax credit for fiscal year 2012. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities along with net operating loss and tax credit carryovers.

We record a valuation allowance against our deferred tax assets to reduce the net carrying value to an amount that we believe is more likely than not to be realized. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was \$24.3 million and \$22.6 million at September 30, 2013 and December 31, 2012, respectively.

We have not provided for withholding and U.S. taxes for the unremitted earnings of certain non-U.S. subsidiaries because we have currently reinvested these earnings indefinitely in these foreign operations. At December 31, 2012, we had approximately \$3,083.5 million in unremitted earnings outside the United States for which withholding and U.S. taxes were not provided. Income tax expense would be incurred if these earnings were remitted to the United States. It is not practicable to estimate the amount of the deferred tax liability on such unremitted earnings. Upon remittance, certain foreign countries impose withholding taxes that are then available, subject to certain limitations,

for use as credits against our U.S. tax liability, if any. We annually update our estimate of unremitted earnings outside the United States after the completion of each fiscal year.

Acquisitions

The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed. Additionally, we must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.

Table of Contents

On February 1, 2012, we purchased the commercial assets related to the selling and distribution of our products from our distributor in Russia for \$3.1 million in cash, net of a \$6.6 million pre-existing net receivable from the distributor, and estimated contingent consideration of \$4.7 million as of the acquisition date. On December 19, 2012, we acquired SkinMedica, Inc., or SkinMedica, for \$348.9 million in cash and contingent consideration with an estimated fair value of \$2.2 million as of the acquisition date. On March 1, 2013, we acquired MAP Pharmaceuticals, Inc., or MAP, for an aggregate purchase price of approximately \$871.7 million, net of cash acquired. On April 12, 2013, we acquired Exemplar Pharma, LLC, or Exemplar, for an aggregate purchase price of approximately \$16.1 million, net of cash acquired. We accounted for these acquisitions as business combinations. The tangible and intangible assets acquired and liabilities assumed in connection with these acquisitions were recognized based on their estimated fair values at the acquisition dates. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. We believe the estimated fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions.

Impairment Evaluations for Goodwill and Intangible Assets

We evaluate goodwill for impairment on an annual basis, or more frequently if we believe indicators of impairment exist. We have identified two reporting units, specialty pharmaceuticals and medical devices, and perform our annual evaluation as of October 1 each year.

For our specialty pharmaceuticals reporting unit, we performed a qualitative assessment to determine whether it is more likely than not that its fair value is less than its carrying amount. For our medical devices reporting unit, we evaluated goodwill for impairment by comparing its carrying value to its estimated fair value. We primarily use the income approach and the market approach that include the discounted cash flow method, the guideline company method, as well as other generally accepted valuation methodologies to determine the fair value. Upon completion of the October 2012 annual impairment assessment, we determined that no impairment was indicated.

On February 1, 2013, we completed our previously announced review of strategic options for maximizing the value of our obesity intervention business, and formally committed to pursue a sale of that business unit. The obesity intervention business was included in our medical devices reporting unit for the annual goodwill impairment evaluation. In the first quarter of 2013, we reported our obesity intervention business as a discontinued operation, and accordingly reduced the value of the net assets held for sale to fair value less costs to sell. In the third quarter of 2013, we reduced the value of the net assets held for sale by an additional amount to reflect an updated estimate of the fair value of the obesity intervention business. The net assets held for sale include a portion of the medical devices reporting unit's goodwill allocated to the obesity intervention business based on the relative fair value as of February 1, 2013 of that business to the portion of the medical devices reporting unit that we will retain. During the first quarter of 2013, we tested the remaining goodwill of the medical devices reporting unit for impairment and concluded that no impairment was indicated.

As of September 30, 2013, we are not aware of any significant indicators of impairment that exist for our goodwill that would require additional analysis.

We also review intangible assets for impairment when events or changes in circumstances indicate that the carrying value of our intangible assets may not be recoverable. An impairment in the carrying value of an intangible asset is recognized whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value.

Significant management judgment is required in the forecasts of future operating results that are used in our impairment evaluations. The estimates we have used are consistent with the plans and estimates that we use to manage our business. It is possible, however, that the plans may change and estimates used may prove to be inaccurate. If our actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, we could incur future impairment charges.

Continuing Operations

Headquartered in Irvine, California, we are a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential — to see more clearly, move more freely and express themselves more fully. We

discover, develop and commercialize a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world.

We are also a pioneer in specialty pharmaceutical, biologic and medical device research and development. Our research and development efforts are focused on products and technologies related to the many specialty areas in which we currently operate as well as new specialty areas where unmet medical needs are significant. We supplement our own research and development

Table of Contents

activities with our commitment to identify and obtain new technologies through in-licensing, research collaborations, joint ventures and acquisitions. At September 30, 2013, we employed approximately 11,400 persons around the world. Our principal geographic markets are the United States, Europe, Latin America and Asia Pacific.

Results of Continuing Operations

We operate our business on the basis of two reportable segments — specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a broad range of pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox® for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and physician-dispensed skin care products; and urologics products. The medical devices segment produces a broad range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. We provide global marketing strategy teams to coordinate the development and execution of a consistent marketing strategy for our products in all geographic regions that share similar distribution channels and customers.

Management evaluates our business segments and various global product portfolios on a net sales basis, which is presented below in accordance with GAAP. We also report sales performance using the non-GAAP financial measure of constant currency sales. Constant currency sales represent current period reported sales, adjusted for the translation effect of changes in average foreign exchange rates between the current period and the corresponding period in the prior year. We calculate the currency effect by comparing adjusted current period reported sales, calculated using the monthly average foreign exchange rates for the corresponding period in the prior year, to the actual current period reported sales. We routinely evaluate our net sales performance at constant currency so that sales results can be viewed without the impact of changing foreign currency exchange rates, thereby facilitating period-to-period comparisons of our sales. Generally, when the U.S. dollar either strengthens or weakens against other currencies, the growth at constant currency rates will be higher or lower, respectively, than growth reported at actual exchange rates. The following tables compare net sales by product line within each reportable segment and certain selected pharmaceutical products for the three and nine month periods ended September 30, 2013 and 2012:

Table of Contents

	Three Months Ended		Change in Product Net Sales			Percent Change in Product Net Sales		
	September 30, 2013	September 30, 2012	Total	Performance	Currency	Total	Performance	Currency
(in millions)								
Net Sales by Product Line:								
Specialty Pharmaceuticals:								
Eye Care Pharmaceuticals	\$717.1	\$663.2	\$53.9	\$59.7	\$(5.8)	8.1 %	9.0 %	(0.9)%
Botox®/Neuromodulators	485.7	431.6	54.1	60.2	(6.1)	12.5 %	13.9 %	(1.4)%
Skin Care and Other	127.0	83.7	43.3	43.5	(0.2)	51.7 %	52.0 %	(0.3)%
Total Specialty Pharmaceuticals	1,329.8	1,178.5	151.3	163.4	(12.1)	12.8 %	13.9 %	(1.1)%
Medical Devices:								
Breast Aesthetics	91.9	86.1	5.8	6.5	(0.7)	6.7 %	7.5 %	(0.8)%
Facial Aesthetics	106.7	89.1	17.6	19.0	(1.4)	19.8 %	21.3 %	(1.5)%
Total Medical Devices	198.6	175.2	23.4	25.5	(2.1)	13.4 %	14.6 %	(1.2)%
Total product net sales	\$1,528.4	\$1,353.7	\$174.7	\$188.9	\$(14.2)	12.9 %	14.0 %	(1.1)%
Domestic product net sales	62.5	% 62.1	%					
International product net sales	37.5	% 37.9	%					
Selected Product Net Sales (a):								
Alphagan® P, Alphagan® and Combigan®	\$112.4	\$111.3	\$1.1	\$2.3	\$(1.2)	1.0 %	2.1 %	(1.1)%
Lumigan® Franchise	153.5	152.0	1.5	0.8	0.7	1.0 %	0.5 %	0.5 %
Total Glaucoma Products	267.9	265.8	2.1	2.7	(0.6)	0.8 %	1.0 %	(0.2)%
Restasis®	239.3	198.3	41.0	42.0	(1.0)	20.7 %	21.2 %	(0.5)%
Latisse®	24.4	23.4	1.0	1.2	(0.2)	4.3 %	4.9 %	(0.6)%

Table of Contents

	Nine Months Ended		Change in Product Net		Percent Change	
	September 30, 2013	September 30, 2012	Sales Total	Performance Currency	Total	Performance Currency
(in millions)						
Net Sales by Product Line:						
Specialty Pharmaceuticals:						
Eye Care Pharmaceuticals	\$2,108.1	\$1,986.1	\$122.0	\$134.1	\$(12.1)	6.1 %
Botox [®] /Neuromodulators	1,456.6	1,291.7	164.9	176.0	(11.1)	12.8 %
Skin Care and Other	344.6	252.8	91.8	92.1	(0.3)	36.3 %
Total Specialty Pharmaceuticals	3,909.3	3,530.6	378.7	402.2	(23.5)	10.7 %
Medical Devices:						
Breast Aesthetics	288.3	285.7	2.6	3.9	(1.3)	0.9 %
Facial Aesthetics	340.3	285.2	55.1	57.2	(2.1)	19.3 %
Total Medical Devices	628.6	570.9	57.7	61.1	(3.4)	10.1 %
Total product net sales	\$4,537.9	\$4,101.5	\$436.4	\$463.3	\$(26.9)	10.6 %
Domestic product net sales	61.5	% 60.8	%			
International product net sales	38.5	% 39.2	%			
Selected Product Net Sales (a):						
Alphagan [®] P, Alphagan [®] and Combigan [®]	\$349.2	\$334.7	\$14.5	\$16.4	\$(1.9)	4.3 %
Lumigan [®] Franchise	452.7	452.4	0.3	—	0.3	0.1 %
Total Glaucoma Products	808.7	794.9	13.8	15.6	(1.8)	1.7 %
Restasis [®]	662.4	580.0	82.4	83.5	(1.1)	14.2 %
Latisse [®]	76.6	72.4	4.2	4.5	(0.3)	5.8 %

(a) Percentage change in selected product net sales is calculated on amounts reported to the nearest whole dollar. Total glaucoma products include the Alphagan[®] and Lumigan[®] franchises.

Product Net Sales

Product net sales increased by \$174.7 million in the third quarter of 2013 compared to the third quarter of 2012 due to an increase of \$151.3 million in our specialty pharmaceuticals product net sales and an increase of \$23.4 million in our medical devices product net sales. The increase in specialty pharmaceuticals product net sales is due to increases in product net sales of our eye care pharmaceuticals, Botox[®] and skin care and other product lines. The increase in medical devices product net sales reflects an increase in product net sales of our facial aesthetics and breast aesthetics product lines.

Several of our products, including Botox[®] Cosmetic, Latisse[®], over-the-counter artificial tears, non-prescription aesthetics skin care products, facial aesthetics and breast implant products, as well as, in emerging markets, Botox[®] for therapeutic use and eye care products, are purchased based on consumer choice and have limited reimbursement or are not reimbursable by government or other health care plans and are, therefore, partially or wholly paid for directly by the consumer. As such, the general economic environment and level of consumer spending have a significant effect on our sales of these products.

In the United States, sales of our products that are reimbursable by government health care plans continue to be significantly impacted by the provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively, the PPACA, which extended Medicaid and Medicare benefits to new patient populations and increased Medicaid and Medicare rebates. Additionally, sales of our products in the United States that are reimbursed by managed care programs continue to be impacted by competitive

pricing pressures. In Europe and some other international markets, sales of our products that are reimbursable by government health care plans continue to be impacted by mandatory price reductions, tenders and rebate increases.

Table of Contents

Certain of our products face generic competition. In May 2011, a generic version of our older-generation topical allergy medication Elestat[®] was launched in the United States. In June 2011, the U.S. patent for Tazorac[®] cream, indicated for psoriasis and acne, expired. The U.S. patents for Tazorac[®] gel expire in June 2014. The U.S. Food and Drug Administration, or FDA, has posted guidance regarding requirements for clinical bioequivalence for a generic of tazarotene cream, separately for both psoriasis and acne. We believe that this will require generic manufacturers to conduct a trial, at risk, for both indications. In October 2012, a competitive generic version of Sanctura XR[®] was launched in the United States. Additionally, a generic version of Zymaxid[®], our fluoroquinolone indicated for the treatment of bacterial conjunctivitis, was launched in the United States in October 2013. The U.S. Patent covering Restasis[®] will expire in May 2014. In June 2013, the FDA issued draft bioequivalence guidance that would potentially allow for a generic version of Restasis[®] to be approved in the future without a human clinical trial. In August 2013, we, as well as 22 medical societies, patient groups and consumer groups, provided comments to the FDA on the draft guidance. Our comments, and generally those of these other parties, challenged the legal scientific basis for the FDA's proposed guidance, raised potential patient safety and public health concerns and argued that the proposed non-clinical criteria are inadequate to prove bioequivalence to Restasis[®]. We are currently engaging with the FDA, especially the Office of Generic Drugs, various experts and others to understand what the FDA plans to do with its current draft guidance. We will also consider other legal and regulatory actions to advocate our positions. Our products also compete with generic versions of some branded pharmaceutical products sold by our competitors. Although generic competition in the United States negatively affected our aggregate product net sales in the first nine months of 2013, the impact was not material. We do not currently believe that our aggregate product net sales will be materially impacted in 2013 by generic competition, but we could experience a rapid and significant decline in net sales of certain products if we are unable to successfully maintain or defend our patents and patent applications relating to such products.

Eye care pharmaceuticals product net sales increased in the third quarter of 2013 compared to the third quarter of 2012 in all of our principal geographic markets. The overall increase in total sales in dollars of our eye care pharmaceutical products is primarily due to an increase in sales of Restasis[®], our therapeutic treatment for chronic dry eye disease, an increase in sales of our glaucoma drug Lumigan[®] 0.01%, an increase in sales of Ozurdex[®], our biodegradable, sustained-release steroid implant for the treatment of certain retinal diseases, an increase in sales of Ganfort[™], our Lumigan[®] and timolol combination for the treatment of glaucoma, an increase in sales of Lastacraft[®], our topical allergy medication for the treatment and prevention of itching associated with allergic conjunctivitis, and an increase of \$6.6 million in sales of our artificial tears products, primarily consisting of Refresh[®] and Optive[™] lubricant eye drops, partially offset by a decrease in sales of our older-generation glaucoma drug Lumigan[®] 0.03% and our fluoroquinolone product Zymaxid[®]. Due to the strong acceptance of Lumigan[®] 0.1% in the United States market, we ceased manufacturing Lumigan[®] 0.3% for the U.S. market in the fourth quarter of 2012.

We increased prices on certain eye care pharmaceutical products in the United States in the last six months of 2012 and the first nine months of 2013. Effective January 5, 2013, we increased the published U.S. list price for Restasis[®], Lastacraft[®] and Zymaxid[®] by five percent, Combigan[®] and Alphagan[®] P 0.1% by seven percent, Lumigan[®] 0.1% and Alphagan[®] P 0.15% by eight percent, and Acular[®], Acular LS[®] and Acuvail[®] by eighteen percent. Effective May 18, 2013, we increased the published U.S. list price for Restasis[®], Alphagan[®] P 0.1%, Alphagan[®] P 0.15% and Lastacraft[®] by an additional five percent and Zymaxid[®], Acular[®], Acular LS[®] and Acuvail[®] by an additional six percent. These price increases had a positive net effect on our U.S. sales in the third quarter of 2013 compared to the third quarter of 2012, but the actual net effect is difficult to determine due to the various managed care sales rebate and other incentive programs in which we participate. Wholesaler buying patterns and the change in dollar value of the prescription product mix also affected our reported net sales dollars, although we are unable to determine the impact of these effects.

Total sales of Botox[®] increased in the third quarter of 2013 compared to the third quarter of 2012 due to strong growth in sales for both therapeutic and cosmetic uses. Sales of Botox[®] for therapeutic use increased in all of our principal geographic markets, primarily due to strong growth in sales for the prophylactic treatment of chronic migraine and an increase in sales for the treatment of urinary incontinence and hyperhidrosis. Sales of Botox[®] for cosmetic use increased in the United States, Europe and Asia, partially offset by a decline in sales in Canada due primarily to the

introduction of competitive products in that market. We believe our worldwide market share for neuromodulators, including Botox[®], was approximately 76% in the second quarter of 2013, the last quarter for which market data is available.

In March 2012, a U.S. District Court, after conducting a full trial, ruled that Merz Pharmaceuticals and Merz Aesthetics, or, jointly, Merz, violated California's Uniform Trade Secrets Act and issued an injunction prohibiting Merz from providing, selling or soliciting purchases of Xeomin[®] or its Radiesse[®] dermal filler products, provided that Merz may sell Xeomin[®] in the therapeutic market to customers not identified on court mandated exclusion lists and may sell dermal filler products to certain pre-existing customers. On October 1, 2012, the Company announced that the U.S. District Court had entered an order providing that the injunction related to Xeomin[®] for the facial aesthetics market would remain in place until January 9, 2013. The injunction related to Xeomin[®] for therapeutic use and Radiesse[®] was in effect until November 1, 2012.

Table of Contents

Skin care and other product net sales increased in the third quarter of 2013 compared to the third quarter of 2012 primarily due to an increase of \$21.2 million in sales of Aczone[®], our topical dapsone treatment for acne vulgaris, new product sales of \$19.7 million from a variety of physician dispensed aesthetic skin care products acquired in our recent acquisition of SkinMedica, an increase of \$6.9 million in sales of our topical tazarotene products Tazorac[®], Zorac[®] and Avage[®], and a \$1.0 million increase in sales of Latisse[®], our treatment for inadequate or insufficient eyelashes, partially offset by a decrease of \$5.6 million in sales of our Sanctura[®] franchise products for the treatment of overactive bladder, or OAB, due to a decline in unit volume related to the launch of competitive generic versions of Sanctura XR[®] in the United States since October 2012. The increases in sales of Aczone[®] and our topical tazarotene products Tazorac[®], Zorac[®] and Avage are primarily attributable to an increase in sales volume and an increase in the U.S. list price for these products of five percent that was effective May 18, 2013. The increase in sales of Latisse[®] is primarily attributable to an increase in product sales volume.

We have a policy to attempt to maintain average U.S. wholesaler inventory levels of our specialty pharmaceuticals products at an amount less than eight weeks of our net sales. At September 30, 2013, based on available external and internal information, we believe the amount of average U.S. wholesaler inventories of our specialty pharmaceutical products was near the lower end of our stated policy levels.

Breast aesthetics product net sales, which consist primarily of sales of silicone gel and saline breast implants and tissue expanders, increased in the third quarter of 2013 compared to the third quarter of 2012 due to increases in sales in the United States, Europe and Asia, partially offset by a decrease in sales in Latin America. The increase in sales of breast aesthetics products in the United States was primarily due to a beneficial change in implant product mix to higher priced round and shaped silicone gel products and higher tissue expander unit volume, partially offset by a small decline in implant unit volume. The increase in sales in Asia benefited from a stocking shipment to Japan. The overall decrease in sales of breast aesthetics products in Latin America was primarily due to lower unit volume shipped to distributors in certain markets. Sales of tissue expanders increased \$2.9 million and total sales of silicone gel and saline breast implants and accessories increased \$2.9 million in the third quarter of 2013 compared to the third quarter of 2012.

Facial aesthetics product net sales, which consist primarily of sales of hyaluronic acid-based dermal fillers used to correct facial wrinkles, increased in the third quarter of 2013 compared to the third quarter of 2012 due to strong growth in all of our principal geographic markets. The increase in sales of facial aesthetics products in the United States was due primarily to an overall increase in unit volume due to an expansion of the dermal filler market and an increase in market share. The increase in sales of facial aesthetics products in Europe, Latin America and Asia Pacific was due primarily to recent launches of Juvéderm[®] Voluma[™], Juvéderm[®] Volift[™] and Juvéderm[®] Volbella[™] in those markets.

Foreign currency changes decreased product net sales by \$14.2 million in the third quarter of 2013 compared to the third quarter of 2012, primarily due to the weakening of the Brazilian real, Canadian dollar, Australian dollar and Turkish lira compared to the U.S. dollar, partially offset by the strengthening of the euro compared to the U.S. dollar. U.S. product net sales as a percentage of total product net sales increased by 0.4 percentage points to 62.5% in the third quarter of 2013 compared to U.S. sales of 62.1% in the third quarter of 2012, due primarily to higher sales growth in the U.S. market compared to our international markets for our Botox[®], skin care and other, breast aesthetics and facial aesthetics product lines, partially offset by higher sales growth in international markets compared to the U.S. market for our eye care pharmaceuticals product line.

The \$436.4 million increase in product net sales in the first nine months of 2013 compared to the first nine months of 2012 was the combined result of an increase of \$378.7 million in our specialty pharmaceuticals product net sales and an increase of \$57.7 million in our medical devices product net sales.

The increase in specialty pharmaceuticals product net sales in the first nine months of 2013 compared to the first nine months of 2012 was primarily due to the same factors discussed above with respect to the increase in specialty pharmaceuticals product net sales for the third quarter of 2013. In addition, net sales of Combigan[®], our Alphagan[®] and timolol combination for the treatment of glaucoma increased in the first nine months of 2013 compared to the first nine months of 2012. Sales of Botox[®] for therapeutic use were relatively unchanged in Latin America in the first nine months of 2013 compared to the first nine months of 2012, primarily due to a delay in orders

from our distributor in Venezuela due to the February 2013 currency devaluation and political transition in that country and the negative impact of the Brazilian real exchange rates compared to the U.S. dollar in effect during the first nine months of 2013 compared to the first nine months of 2012. The increase in eye care pharmaceuticals in the first nine months of 2013 compared to the first nine months of 2012 includes an increase of \$9.6 million in sales of our artificial tears products. The increase in skin care and other product net sales in the first nine months of 2013 compared to the first nine months of 2012 primarily includes an increase of \$35.9 million in sales of Aczone[®], new product sales of \$59.5 million due to our recent acquisition of SkinMedica, an increase of \$18.5 million in sales of Tazorac[®], Zorac[®] and Avage[®] and a \$4.2 million increase in sales of Latisse[®], partially offset by a decrease of \$25.0 million in sales of our Sanctura[®] franchise products.

Table of Contents

The increase in medical devices product net sales in the first nine months of 2013 compared to the first nine months of 2012 was primarily due to the same factors discussed above with respect to the increase in medical devices product net sales for the third quarter of 2013. In addition, product net sales in 2013 compared to 2012 were positively impacted by an increase in sales from silicone gel breast implant products in China during 2013. Also, sales of breast aesthetics products in Europe decreased in the first nine months of 2013 compared to the first nine months of 2012 due to extraordinarily high sales and sales growth in the first nine months 2012 following a regulatory action by the French Government to shut down a manufacturer using industrial grade silicone in their breast implants. Many of the resultant revision surgeries occurred with our implants. Sales of tissue expanders increased \$5.9 million in the first nine months of 2013 compared to the first nine months of 2012, and sales of total silicone gel and saline breast implants and accessories decreased \$3.3 million during the same period.

Foreign currency changes decreased product net sales by \$26.9 million in the first nine months of 2013 compared to the first nine months of 2012, primarily due to the weakening of the Brazilian real, Canadian dollar, Australian dollar, U.K. pound, Turkish lira and Indian rupee compared to the U.S. dollar, partially offset by the strengthening of the euro and Mexican peso compared to the U.S. dollar.

U.S. sales as a percentage of total product net sales increased by 0.7 percentage points to 61.5% in the first nine months of 2013 compared to U.S. sales of 60.8% in the first nine months of 2012, due primarily to higher sales growth in the U.S. market compared to our international markets for our Botox® and skin care and other product lines, partially offset by higher sales growth in international markets compared to the U.S. market for our eye care pharmaceuticals product line.

Other Revenues

Other revenues increased \$7.5 million to \$30.3 million in the third quarter of 2013 compared to \$22.8 million in the third quarter of 2012. The increase in other revenues is primarily due to an increase in royalty income from sales of brimonidine products in the United States under a license agreement with Alcon, Inc., or Alcon, and an increase in sales of Aiphagan® in Japan under a license agreement with Senju.

Other revenues increased \$5.1 million to \$78.1 million in the first nine months of 2013 compared to \$73.0 million in the first nine months of 2012. The increase in other revenues is primarily due to an increase in royalty income, partially offset by a decline in substantive milestone event revenue. No substantive milestone event revenue was recorded in the first nine months of 2013. In the first nine months of 2012, other revenues included the achievement of substantive milestones related to the approval of Aiphagan® in Japan and the achievement of two sales milestones related to sales of Lumigan® in Japan. The increase in royalty income in the first nine months of 2013 compared to the first nine months of 2012 is primarily due to an increase in sales of Aiphagan® in Japan under a license agreement with Senju, an increase in sales of brimonidine products in the United States under a license agreement with Alcon and an increase in sales of Botox® for therapeutic use in Japan and China under a licensing agreement with GlaxoSmithKline, partially offset by a decrease in royalties from sales of Lumigan® in Japan under a license agreement with Senju, which were negatively impacted by the Japanese yen exchange rates in effect during the first nine months of 2013 compared to the first nine months of 2012.

Cost of Sales

Cost of sales increased \$9.3 million, or 5.1%, in the third quarter of 2013 to \$192.2 million, or 12.6% of product net sales, compared to \$182.9 million, or 13.5% of product net sales in the third quarter of 2012. The increase in cost of sales primarily resulted from the 12.9% increase in total product net sales, partially offset by a decrease in cost of sales as a percentage of product net sales primarily due to lower royalty expenses, lower provisions for inventory reserves and beneficial changes in standard costs and product mix.

Cost of sales increased \$23.0 million, or 4.0%, in the first nine months of 2013 to \$591.2 million, or 13.0% of product net sales, compared to \$568.2 million, or 13.9% of product net sales in the first nine months of 2012. Cost of sales in the first nine months of 2013 includes \$8.9 million for the purchase accounting fair market value inventory adjustment rollout related to our acquisition of SkinMedica. Cost of sales in the first nine months of 2012 includes \$0.3 million for the purchase accounting fair market value inventory adjustment rollout related to the purchase of our distributor's business in Russia. Excluding the effect of the charges described above, cost of sales increased \$14.4 million, or 2.5%, to \$582.3 million, or 12.8% of product net sales in the first nine months of 2013 compared to \$567.9 million, or 13.8%

of product net sales, in the first nine months of 2012. This increase in cost of sales primarily resulted from the 10.6% increase in total product net sales, partially offset by a decrease in cost of sales as a percentage of product net sales primarily due to lower royalty expenses, lower provisions for inventory reserves, and beneficial changes in standard costs and product mix.

Table of Contents

Selling, General and Administrative

Selling, general and administrative, or SG&A, expenses increased \$66.4 million, or 12.7%, to \$589.3 million, or 38.6% of product net sales, in the third quarter of 2013 compared to \$522.9 million, or 38.6% of product net sales, in the third quarter of 2012. SG&A expenses in the third quarter of 2013 include \$3.4 million of transaction and integration costs related to business combinations and license agreements, a \$1.5 million charge related to the change in fair value of contingent consideration liabilities associated with certain business combinations, expenses of \$1.4 million related to the realignment of various business functions and expenses of \$0.1 million for external costs of stockholder derivative litigation associated with the 2010 global settlement with the U.S. Department of Justice, or DOJ, regarding our past U.S. sales and marketing practices relating to certain therapeutic uses of Botox®. SG&A expenses in the third quarter of 2012 include expenses of \$0.5 million for external costs of stockholder derivative litigation associated with the 2010 global settlement with the DOJ discussed above and a \$2.4 million charge related to the change in fair value of contingent consideration liabilities associated with certain business combinations. Excluding the effect of the items described above, SG&A expenses increased \$62.9 million, or 12.1%, to \$582.9 million, or 38.1% of product net sales, in the third quarter of 2013 compared to \$520.0 million, or 38.4% of product net sales in the third quarter of 2012. The increase in SG&A expenses in dollars, excluding the charges described above, primarily relates to increases in selling expenses and promotion expenses. The increase in selling expenses in the third quarter of 2013 compared to the third quarter of 2012 principally relates to increased personnel and related incentive compensation costs that support the 12.9% increase in product net sales, including the acquisition of the SkinMedica sales force and other sales force expansions in the United States, Europe and Asia. The increase in promotion expenses is primarily due to an increase in direct-to-consumer advertising in the United States for Aczone®, Botox® for the treatment of chronic migraine and Restasis®. General and administrative expenses declined slightly in the third quarter of 2013 compared to the third quarter of 2012. The decrease in general and administrative expenses primarily relates to a reduction in the estimated expense for our share of the annual non-deductible fee on entities that sell branded prescription drugs to specified government programs in the United States and a decrease in losses from the disposal of fixed assets and general insurance costs, partially offset by higher personnel and related incentive compensation costs, the new medical device excise tax in the United States and higher facilities costs. SG&A expenses increased \$153.2 million, or 9.3%, to \$1,804.0 million, or 39.8% of product net sales, in the first nine months of 2013 compared to \$1,650.8 million, or 40.2% of product net sales, in the first nine months of 2012. SG&A expenses in the first nine months of 2013 include \$18.5 million of transaction and integration costs related to business combinations and license agreements, a \$4.8 million charge related to the change in fair value of contingent consideration liabilities associated with certain business combinations, expenses of \$1.6 million related to the realignment of various business functions and expenses of \$3.6 million for external costs of stockholder derivative litigation associated with the 2010 global settlement with the DOJ discussed above and other legal contingency expenses. SG&A expenses in the first nine months of 2012 include \$8.9 million of stockholder derivative litigation costs associated with the 2010 global settlement with the DOJ discussed above and other legal contingency expenses and a \$15.8 million charge related to the change in fair value of contingent consideration liabilities associated with certain business combinations. Excluding the effect of the items described above, SG&A expenses increased \$149.4 million, or 9.2%, to \$1,775.5 million, or 39.1% of product net sales, in the first nine months of 2013 compared to \$1,626.1 million, or 39.6% of product net sales in the first nine months of 2012. The increase in SG&A expenses in dollars, excluding the charges described above, primarily relates to increases in selling expenses, promotion expenses, and general and administrative expenses. The increase in selling expenses and promotion expenses in the first nine months of 2013 was primarily due to the same factors discussed with regard to the increase in these expenses in the third quarter of 2013 compared to the third quarter of 2012. The increase in general and administrative expenses primarily relates to higher personnel and related incentive compensation costs, the new medical device excise tax in the United States, an increase in bad debt expense and higher facilities costs, partially offset by a decrease in legal expenses, losses from the disposal of fixed assets and general insurance costs, and a reduction in the estimated expense for our share of the annual non-deductible fee on entities that sell branded prescription drugs to specified government programs in the United States.

Under the provisions of the PPACA, companies that sell branded prescription drugs or biologics to specified government programs in the United States are subject to an annual non-deductible fee based on the company's relative market share of branded prescription drugs or biologics sold to the specified government programs. The non-deductible fee is recorded in SG&A expenses, and the related full year 2013 expense is expected to be approximately \$24 million to \$27 million. Also under the provisions of the PPACA, the Company is required to pay a tax deductible excise tax of 2.3% on the sale of certain medical devices beginning January 1, 2013. The excise tax is recorded in SG&A expenses, and the related full year 2013 expense is expected to be approximately \$7 million to \$10 million.

Research and Development

We believe that our future medium- and long-term revenue and cash flows are most likely to be affected by the successful development and approval of our significant late-stage research and development candidates. As of September 30, 2013, we have the following significant R&D projects in late-stage development:

Table of Contents

Latisse® (U.S - Phase III) for brow

Levadex® (U.S. - Filed/Allergan addressing FDA Complete Response Letter) for migraine

Ozurdex® (U.S. and Europe - Filed) for diabetic macular edema

Restasis® (Europe - Phase III) for ocular surface disease

Ser-120 (U.S. - Phase III) for nocturia (in collaboration with Serenity)

Botox® (U.S - Phase III) for juvenile cerebral palsy

In December 2012, we announced that Botox® received a positive opinion from the Irish Medicines Board for the treatment of idiopathic overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medications. This is an important step towards securing national licenses in the 14 European countries involved in the Mutual Recognition Procedure.

In January 2013, we announced that the FDA approved Botox® for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

In January 2013, we restructured our collaboration agreement with Spectrum Pharmaceuticals, Inc., or Spectrum, for the development of apaziquone, pursuant to which Spectrum reacquired all rights from us under the collaboration agreement in exchange for agreeing to pay us a royalty on future net sales of licensed products. We have no further obligation under the agreement to share development costs or perform any development, regulatory or other activities.

In February 2013, we announced that the FDA approved our Natrelle®410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.

In March 2013, we completed the acquisition of MAP (previously, our collaboration partner for Levadex®). In April 2013, we announced that we received a Complete Response Letter, or CRL, from the FDA related to the Levadex® filing that noted concerns with the third-party canister filling unit manufacturer, Exemplar Pharma, LLC, or Exemplar. In April 2013, in order to secure our supply chain, we acquired Exemplar for approximately \$16.1 million. We are on track for filing, by year end, all the data required by the FDA in the CRL and anticipate approval in the second quarter of 2014.

In September 2013, we announced that the FDA approved Botox® for an additional cosmetic indication to temporarily treat moderate to severe lateral canthal lines, commonly known as crow's feet lines. Botox® is the first and only product of its kind approved for this indication in the United States.

In October 2013, we announced that the FDA approved Juvéderm® Voluma™XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21.

In October 2013, we announced that VISTABEL® received a positive opinion from the Agence Nationale de Sécurité du Médicament et des Produits de Santé for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's feet lines) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown in adult patients. This is an important step towards securing national licences in the twenty seven countries of the European Union as well as Norway and Iceland.

In addition to the significant R&D projects in late stage development described above, in May 2013, we provided an update on certain important Phase II projects — namely, the development of therapeutic DARP[®] products and bimatoprost for scalp hair growth. Regarding development efforts of therapeutic DARP[®] products, we have completed analysis of data from the randomized controlled Phase II trial comparing two doses of the anti-VEGF DARP[®] and Lucentis® (ranibizumab), which suggest some product differentiation between DARP[®] and Lucentis® but do not support directly moving to Phase III. During the second quarter of 2013, we started to recruit patients into an additional Phase II study to more completely assess safety and efficacy and to guide the Phase III study design. In this Phase II study, patients are randomized to one of two doses of the anti-VEGF DARP[®] or ranibizumab. This study employs the conventional use of three loading doses to eliminate existing retinal fluid and then assesses the duration of this treatment effect. Regarding bimatoprost for scalp hair growth, the results of the Phase II trial in male and female hair loss indicated that the formulation was well tolerated but did not provide sufficient efficacy to proceed directly to Phase III. We began enrolling patients in the third quarter of 2013 in the first of two additional planned Phase II studies that include trials using a substantially higher concentration of bimatoprost.

For management purposes, we accumulate direct costs for R&D projects, but do not allocate all indirect project costs, such as R&D administration, infrastructure and regulatory affairs costs, to specific R&D projects. Additionally, R&D expense includes upfront payments to license or purchase in-process R&D assets that have not achieved regulatory approval. Our overall R&D expenses are not materially concentrated in any specific project or stage of development. The following table sets forth direct costs for our late-stage projects (which include candidates in Phase III clinical trials) and other R&D projects, upfront payments to

41

Table of Contents

license or purchase in-process R&D assets and all other R&D expenses for the three and nine month periods ended September 30, 2013 and 2012:

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
	(in millions)			
Direct costs for:				
Late-stage projects	\$59.3	\$43.5	\$173.5	\$137.5
Other R&D projects	164.8	157.6	509.8	459.9
Upfront payments to license or purchase in-process R&D assets	6.5	62.5	6.5	62.5
Other R&D expenses	27.0	26.2	83.1	77.6
Total	\$257.6	\$289.8	\$772.9	\$737.5

R&D expenses decreased \$32.2 million, or 11.1%, to \$257.6 million in the third quarter of 2013, or 16.9% of product net sales, compared to \$289.8 million, or 21.4% of product net sales in the third quarter of 2012. R&D expenses in the third quarter of 2013 include \$6.5 million for an upfront payment associated with the in-licensing of a technology for the treatment of ocular disease that has not yet achieved regulatory approval. R&D expenses in the third quarter of 2012 include an aggregate charge of \$62.5 million for upfront payments associated with two agreements for the in-licensing of technologies for the treatment of serious ophthalmic diseases, including age-related macular degeneration, from Molecular Partners AG that have not yet achieved regulatory approval. Excluding the effect of the charges described above, R&D expenses increased \$23.8 million, or 10.5%, to \$251.1 million in the third quarter of 2013, or 16.4% of product net sales, compared to \$227.3 million, or 16.8% of product net sales in the third quarter of 2012. The increase in R&D expenses in dollars was primarily due to increased spending on next generation eye care pharmaceuticals products for the treatment of glaucoma and retinal diseases, including the DARPin[®] development programs, the development of technology for the treatment of rosacea acquired in the Vicept acquisition, increased spending on Botox[®] for the treatment of movement disorders, including juvenile cerebral palsy, increased spending on potential new treatment applications for Latisse[®], an increase in costs associated with our collaboration with Serenity Pharmaceuticals, LLC related to Ser-120 for the treatment of nocturia, increased spending on the development of tissue reinforcement technology acquired in the Serica Technologies, Inc. acquisition, and new expenses for the development of Levadex[®] for the acute treatment of migraine acquired in the MAP acquisition, partially offset by a decrease in expenses associated with our restructured collaboration with Spectrum related to the development of apaziquone, a decrease in spending on Botox[®] for the treatment of crow's feet and a decrease in expenses for new technology discovery programs.

R&D expenses increased \$35.4 million, or 4.8%, to \$772.9 million in the first nine months of 2013, or 17.0% of product net sales, compared to \$737.5 million, or 18.0% of product net sales in the first nine months of 2012. R&D expenses in the first nine months of 2013 include \$6.5 million for an upfront payment associated with the in-licensing of a technology for the treatment of ocular disease that has not yet achieved regulatory approval. R&D expenses in the first nine months of 2012 include an aggregate charge of \$62.5 million for upfront payments associated with two agreements for the in-licensing of technologies for the treatment of serious ophthalmic diseases, including age-related macular degeneration, from Molecular Partners AG that have not yet achieved regulatory approval. Excluding the effect of the charges described above, R&D expenses increased \$91.4 million, or 13.5%, to \$766.4 million in the first nine months of 2013, or 16.9% of product net sales, compared to \$675.0 million, or 16.5% of product net sales in the first nine months of 2012. The increase in R&D expenses in the first nine months of 2013 was primarily due to the same factors described above related to the increase in R&D expenses in the third quarter of 2013 compared to the third quarter of 2012.

Amortization of Intangible Assets

Amortization of intangible assets increased \$6.0 million to \$28.8 million in the third quarter of 2013, or 1.9% of product net sales, compared to \$22.8 million, or 1.7% of product net sales, in the third quarter of 2012. The increase in

amortization expense is primarily due to an increase in the balance of intangible assets subject to amortization, including intangible assets that we acquired in connection with our March 2013 acquisition of MAP and our December 2012 acquisition of SkinMedica, partially offset by a decline in amortization expense associated with certain licensing assets that became fully amortized at the end of the first quarter of 2013, and intangible assets associated with Sanctura XR[®], which became fully amortized at the end of 2012.

Amortization of intangible assets increased \$21.3 million to \$88.5 million in the first nine months of 2013, or 2.0% of product net sales, compared to \$67.2 million, or 1.6% of product net sales, in the first nine months of 2012. The increase in amortization expense is primarily due to the same factors described above with respect to the increase in amortization expense in the third quarter of 2013 compared to the third quarter of 2012.

Table of Contents

Restructuring Charges and Integration Costs

In connection with our March 2013 acquisition of MAP, our April 2013 acquisition of Exemplar and our December 2012 acquisition of SkinMedica, we initiated restructuring activities to integrate the operations of the acquired businesses with our operations and to capture synergies through the centralization of certain research and development, manufacturing, general and administrative and commercial functions. The restructuring charges primarily consist of employee severance and other one-time termination benefits for approximately 111 people. In the first quarter of 2013, we recorded \$4.3 million of restructuring charges. In the second quarter of 2013, we recorded a \$0.9 million restructuring charge reversal. In the third quarter of 2013, we recorded an additional \$0.6 million of restructuring charges.

Included in the nine month period ended September 30, 2013 are \$0.9 million of restructuring charges for employee severance and other one-time termination benefits related to the realignment of various business functions initiated in 2013. Included in the three and nine month periods ended September 30, 2012 are \$0.7 million of restructuring charges for employee severance and other one-time termination benefits related to the realignment of various business functions initiated in 2012. Included in the three and nine month periods ended September 30, 2012 are a \$0.1 million restructuring charge reversal and \$0.8 million of restructuring charges, respectively, related to restructuring activities initiated in prior years.

Included in the three month period ended September 30, 2013 are \$3.4 million of SG&A expenses and in the nine month period ended September 30, 2013 \$0.1 million of cost of sales and \$18.5 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. Included in the three month period ended September 30, 2012 are \$0.1 million of SG&A expenses and in the nine month period ended September 30, 2012 \$0.1 million of cost of sales and \$0.6 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. For the nine month period ended September 30, 2013, these costs primarily consist of investment banking and legal fees. In addition, included in the three month period ended September 30, 2013 are \$1.4 million of SG&A expenses and \$0.2 million of R&D expenses and in the nine month period ended September 30, 2013 \$1.6 million of SG&A expenses and \$0.9 million of R&D expenses related to the realignment of various business functions. Included in the three month period ended September 30, 2012 are \$0.3 million of SG&A expenses and in the nine month period ended September 30, 2012 \$0.8 million of SG&A expenses and \$0.3 million of R&D expenses related to the realignment of various business functions. The SG&A and R&D expenses related to the realignment of various business functions primarily consist of one-time termination benefits earned based on specified retention periods and losses on the disposal of fixed assets.

Operating Income

Management evaluates business segment performance on an operating income basis exclusive of general and administrative expenses and other indirect costs, legal settlement expenses, impairment of intangible assets and related costs, restructuring charges, in-process research and development expenses, amortization of certain identifiable intangible assets related to business combinations, asset acquisitions and related capitalized licensing costs and certain other adjustments, which are not allocated to our business segments for performance assessment by our chief operating decision maker. Other adjustments excluded from our business segments for purposes of performance assessment represent income or expenses that do not reflect, according to established Company-defined criteria, operating income or expenses associated with our core business activities.

For the third quarter of 2013, general and administrative expenses, other indirect costs and other adjustments not allocated to our business segments for purposes of performance assessment consisted of general and administrative expenses of \$114.3 million, stockholder derivative litigation costs of \$0.1 million in connection with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to Botox®, charges of \$1.5 million for changes in the fair value of contingent consideration liabilities, integration and transaction costs of \$3.0 million associated with the purchase of various businesses, expenses of \$1.6 million related to the realignment of various business functions initiated in 2013, an upfront licensing fee of \$6.5 million for technology that has not achieved regulatory approval and related transaction costs of \$0.1 million, transaction costs of \$0.3 million associated with a licensing agreement with Medytox, Inc. and other net indirect costs of \$6.0 million.

For the third quarter of 2012, general and administrative expenses, other indirect costs and other adjustments not allocated to our business segments for purposes of performance assessment consisted of general and administrative expenses of \$105.0 million, upfront licensing fees of \$62.5 million paid to Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of \$0.1 million, stockholder derivative litigation costs of \$0.5 million in connection with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to Botox[®], charges of \$2.4 million for changes in the fair value of contingent consideration liabilities, expenses related to the 2012 restructuring and realignment initiatives of \$0.3 million and other net indirect costs of \$7.1 million.

Table of Contents

For the first nine months of 2013, general and administrative expenses, other indirect costs and other adjustments not allocated to our business segments for purposes of performance assessment consisted of general and administrative expenses of \$335.4 million, aggregate charges of \$3.6 million for stockholder derivative litigation costs in connection with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to Botox® and other legal contingency expenses, charges of \$4.8 million for changes in the fair value of contingent consideration liabilities, a purchase accounting fair market value inventory adjustment of \$8.9 million associated with the acquisition of SkinMedica, integration and transaction costs of \$18.2 million associated with the purchase of various businesses, expenses of \$2.5 million related to the realignment of various business functions initiated in 2013, an upfront licensing fee of \$6.5 million for technology that has not achieved regulatory approval and related transaction costs of \$0.1 million, transaction costs of \$0.3 million associated with a licensing agreement with Medytox, Inc. and other net indirect costs of \$20.9 million.

For the first nine months of 2012, general and administrative expenses, other indirect costs and other adjustments not allocated to our business segments for purposes of performance assessment consisted of general and administrative expenses of \$314.0 million, upfront licensing fees of \$62.5 million paid to Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of \$0.1 million, aggregate charges of \$8.9 million for stockholder derivative litigation costs in connection with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to Botox® and other legal contingency expenses, charges of \$15.8 million for changes in the fair value of contingent consideration liabilities, a purchase accounting fair market value inventory adjustment of \$0.3 million and integration and transaction costs of \$0.6 million associated with the purchase of our distributor's business related to our products in Russia, expenses related to the 2012 restructuring and realignment initiatives of \$1.1 million and other net indirect costs of \$15.6 million.

The following table presents operating income for each reportable segment for the three and nine month periods ended September 30, 2013 and 2012 and a reconciliation of our segments' operating income to consolidated operating income:

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Operating income:				
Specialty pharmaceuticals	\$593.4	\$503.4	\$1,652.8	\$1,449.8
Medical devices	58.5	49.6	188.2	169.4
Total segments	651.9	553.0	1,841.0	1,619.2
General and administrative expenses, other indirect costs and other adjustments	133.4	177.9	401.2	418.9
Amortization of intangible assets (a)	27.7	17.0	80.4	49.5
Restructuring charges	0.6	0.6	4.9	1.5
Total operating income	\$490.2	\$357.5	\$1,354.5	\$1,149.3

(a) Represents amortization of certain identifiable intangible assets related to business combinations, asset acquisitions and related capitalized licensing costs, as applicable.

Our consolidated operating income in the third quarter of 2013 was \$490.2 million, or 32.1% of product net sales, compared to consolidated operating income of \$357.5 million, or 26.4% of product net sales in the third quarter of 2012. The \$132.7 million increase in consolidated operating income was due to a \$174.7 million increase in product net sales, a \$7.5 million increase in other revenues and a \$32.2 million decrease in R&D expenses, partially offset by a \$9.3 million increase in cost of sales, a \$66.4 million increase in SG&A expenses and a \$6.0 million increase in amortization of intangible assets.

Our specialty pharmaceuticals segment operating income in the third quarter of 2013 was \$593.4 million, compared to operating income of \$503.4 million in the third quarter of 2012. The \$90.0 million increase in our specialty pharmaceuticals segment operating income was due primarily to an increase in product net sales across all product

lines, partially offset by an increase in selling, promotion and R&D expenses.

Our medical devices segment operating income in the third quarter of 2013 was \$58.5 million, compared to operating income of \$49.6 million in the third quarter of 2012. The \$8.9 million increase in our medical devices segment operating income was due primarily to an increase in product net sales of our facial aesthetics and breast aesthetics product lines, partially offset by an increase in selling, promotion and R&D expenses.

Table of Contents

Our consolidated operating income in the first nine months of 2013 was \$1,354.5 million, or 29.8% of product net sales, compared to consolidated operating income of \$1,149.3 million, or 28.0% of product net sales in the first nine months of 2012. The \$205.2 million increase in consolidated operating income was due to a \$436.4 million increase in product net sales and a \$5.1 million increase in other revenues, partially offset by a \$23.0 million increase in cost of sales, a \$153.2 million increase in SG&A expenses, a \$35.4 million increase in R&D expenses, a \$21.3 million increase in amortization of intangible assets and a \$3.4 million increase in restructuring charges.

Our specialty pharmaceuticals segment operating income in the first nine months of 2013 was \$1,652.8 million, compared to operating income of \$1,449.8 million in the first nine months of 2012. The \$203.0 million increase in our specialty pharmaceuticals segment operating income was due primarily to the same factors discussed above with respect to the increase in our specialty pharmaceuticals operating income in the third quarter of 2013 compared to the third quarter of 2012.

Our medical devices segment operating income in the first nine months of 2013 was \$188.2 million, compared to operating income of \$169.4 million in the first nine months of 2012. The \$18.8 million increase in our medical devices segment operating income was due primarily to the same factors discussed above with respect to the increase in our medical devices operating income in the third quarter of 2013 compared to the third quarter of 2012.

Non-Operating Income and Expense

Total net non-operating expense in the third quarter of 2013 was \$33.4 million compared to total net non-operating expense of \$23.2 million in the third quarter of 2012. Interest income decreased \$0.4 million to \$1.5 million in the third quarter of 2013 compared to \$1.9 million in the third quarter of 2012. Interest expense increased \$3.5 million to \$19.4 million in the third quarter of 2013 compared to \$15.9 million in the third quarter of 2012. Interest expense increased primarily due to the issuance in March 2013 of our 1.35% Senior Notes due 2018, or 2018 Notes, and our 2.80% Senior Notes due 2023, or 2023 Notes. Other, net expense was \$15.5 million and \$9.2 million in the third quarter of 2013 and 2012, respectively, consisting primarily of net losses on foreign currency derivative instruments and other foreign currency transactions.

Total net non-operating expense in the first nine months of 2013 was \$64.7 million compared to total net non-operating expense of \$63.3 million in the first nine months of 2012. Interest income increased \$0.3 million to \$5.1 million in the first nine months of 2013 compared to \$4.8 million in the first nine months of 2012. Interest expense increased \$8.0 million to \$56.8 million in the first nine months of 2013 compared to \$48.8 million in the first nine months of 2012. Interest expense increased primarily due to an increase in accrued statutory interest resulting from a change in estimate related to uncertain tax positions and an increase in interest expense due to the issuance in March 2013 of our 2018 Notes and our 2023 Notes. Other, net expense was \$13.0 million in the first nine months of 2013, consisting primarily of \$10.1 million in net losses on foreign currency derivative instruments and other foreign currency transactions and a loss of \$3.7 million related to the impairment of a non-marketable third party equity investment, partially offset by a gain of \$0.7 million on the sale of a third party equity investment. Other, net expense was \$19.3 million in the first nine months of 2012, consisting primarily of net losses on foreign currency derivative instruments and other foreign currency transactions.

Income Taxes

Our effective tax rate for the third quarter of 2013 was 27.1%. Our effective tax rate for the first nine months of 2013 was 25.6%. Included in our earnings before income taxes for the first nine months of 2013 are charges related to changes in the fair value of contingent consideration associated with certain business combination agreements of \$4.8 million, the fair market value inventory adjustment rollout related to the acquisition of SkinMedica of \$8.9 million, external costs of stockholder derivative litigation associated with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to certain therapeutic uses of Botox® and other legal contingency expenses of \$3.6 million, transaction and integration costs associated with business combinations and license agreements of \$18.6 million, a loss of \$3.7 million related to the impairment of a non-marketable third party equity investment and restructuring charges of \$4.9 million. In the first nine months of 2013 we recorded no income tax benefit related to the changes in the fair value of contingent consideration liabilities, \$3.3 million of income tax benefits related to the fair market value inventory adjustment rollout related to the acquisition of SkinMedica, \$0.2 million of income tax benefits related to external costs of stockholder derivative litigation associated with the 2010

global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to certain therapeutic uses of Botox[®] and other legal contingency expenses, \$4.5 million of income tax benefits related to transaction and integration costs associated with business combinations and license agreements, \$1.3 million of income tax benefits related to the impairment of a non-marketable third party equity investment and \$1.5 million of income tax benefits related to the restructuring charges. In the first nine months of 2013, we also recorded an income tax benefit of \$15.4 million for the retroactive benefit of the U.S. federal research and development tax credit for the 2012 fiscal year that was signed into law on January 2, 2013. Excluding the impact of the pre-tax charges of \$44.5 million and the income tax benefits of \$26.2 million for the items discussed above, our adjusted effective tax rate for the first nine months of 2013 was 26.7%. We believe that the use of an adjusted effective tax rate provides a more meaningful measure

Table of Contents

of the impact of income taxes on our results of operations because it excludes the effect of certain items that are not included as part of our core business activities. This allows investors to better determine the effective tax rate associated with our core business activities.

The calculation of our adjusted effective tax rate for the first nine months of 2013 is summarized below:

	(in millions)	
Earnings from continuing operations before income taxes, as reported	\$1,289.8	
Changes in the fair value of contingent consideration liabilities related to business combinations	4.8	
Fair market value inventory adjustment rollout related to the acquisition of SkinMedica	8.9	
External costs for stockholder derivative litigation and other legal contingency expenses	3.6	
Transaction and integration costs associated with business combinations and license agreements	18.6	
Impairment of a non-marketable third party equity investment	3.7	
Restructuring charges	4.9	
	\$1,334.3	
Provision for income taxes, as reported	\$329.9	
Income tax benefit (provision) for:		
Changes in the fair value of contingent consideration liabilities related to business combinations	—	
Fair market value inventory adjustment rollout related to the acquisition of SkinMedica	3.3	
External costs for stockholder derivative litigation and legal contingency expenses	0.2	
Transaction and integration costs associated with business combinations and license agreements	4.5	
Impairment of a non-marketable third party equity investment	1.3	
Restructuring charges	1.5	
2012 retroactive U.S. federal research and development tax credit	15.4	
	\$356.1	
Adjusted effective tax rate	26.7	%

Our effective tax rates for the third quarter and first nine months of 2012 were 24.3% and 28.3%, respectively. Our effective tax rate for the year ended December 31, 2012 was 28.1%. Included in our earnings before income taxes for the fiscal year 2012 are charges related to changes in the fair value of contingent consideration associated with certain business combination agreements of \$5.4 million, upfront payments of \$62.5 million associated with two agreements for the in-licensing of technologies from Molecular Partners AG, the fair market value inventory adjustment rollout and integration costs related to the purchase of a distributor's business in Russia of \$0.9 million, external costs of stockholder derivative litigation and other legal costs associated with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to certain therapeutic uses of Botox® and other legal contingency expenses of \$9.7 million, \$0.9 million of interest expense associated with changes in estimated taxes related to uncertain tax positions included in prior year filings, restructuring charges of \$1.5 million and impairment of intangible assets and related costs of \$22.3 million. In 2012 we recorded no income tax benefits related to the changes in the fair value of contingent consideration liabilities, \$15.7 million of income tax benefits related to the upfront payments associated with the two agreements for the in-licensing of technologies from Molecular Partners AG, \$0.1 million of income tax benefits related to the fair market value inventory adjustment rollout and integration costs related to the purchase of a distributor's business in Russia, \$1.3 million of income tax benefits related to external costs of stockholder derivative litigation and other legal costs associated with the 2010 global settlement with the DOJ regarding our past U.S. sales and marketing practices relating to certain therapeutic uses of Botox® and other legal contingency expenses, income tax benefits of \$0.3 million related to interest expense associated with changes in estimated taxes related to uncertain tax positions included in prior year filings, \$0.6 million of income tax benefits related to the restructuring charges and \$8.2 million of income tax benefits related to the impairment of intangible assets and related costs. In 2012 we also recorded an income tax provision of \$7.7 million for changes in estimated taxes related to uncertain tax positions included in prior year filings. Excluding the impact of the pre-tax charges of \$103.2 million and the net income tax benefits of \$18.5 million for the items discussed above, our adjusted effective tax rate for 2012 was 27.5%.

Table of Contents

The calculation of our adjusted effective tax rate for 2012 is summarized below:

	2012	
	(in millions)	
Earnings from continuing operations before income taxes	\$1,531.0	
Changes in the fair value of contingent consideration liabilities related to business combinations	5.4	
Upfront payments associated with two agreements for the in-licensing of technologies from Molecular Partners AG	62.5	
Fair market value inventory adjustment rollout and integration costs related to the purchase of a distributor's business in Russia	0.9	
External costs for stockholder derivative litigation and other legal contingency expenses	9.7	
Interest expense associated with changes in estimated taxes related to uncertain tax positions in prior year filings	0.9	
Restructuring charges	1.5	
Impairment of intangible assets and related costs	22.3	
	\$1,634.2	
Provision for income taxes	\$430.3	
Income tax benefit (provision) for:		
Changes in the fair value of contingent consideration liabilities related to business combinations	—	
Upfront payments associated with two agreements for the in-licensing of technologies from Molecular Partners AG	15.7	
Fair market value inventory adjustment rollout and integration costs related to the purchase of a distributor's business in Russia	0.1	
External costs for stockholder derivative litigation and other legal contingency expenses	1.3	
Interest expense associated with changes in estimated taxes related to uncertain tax positions in prior year filings	0.3	
Restructuring charges	0.6	
Impairment of intangible assets and related costs	8.2	
Changes in estimated taxes related to uncertain tax positions in prior year filings	(7.7)
	\$448.8	
Adjusted effective tax rate	27.5	%

The decrease in the adjusted effective tax rate to 26.7% in the first nine months of 2013 compared to the adjusted effective tax rate for the year ended December 31, 2012 of 27.5% is primarily attributable to the beneficial impact of the U.S. federal research and development tax credit, which is included in our estimated annual effective tax rate for 2013, but was not available in 2012, partially offset by a small negative change in other tax positions affecting unrecognized tax benefits.

Earnings from Continuing Operations

Our earnings from continuing operations in the third quarter of 2013 were \$332.9 million compared to earnings from continuing operations of \$252.9 million in the third quarter of 2012. The \$80.0 million increase in earnings from continuing operations was primarily the result of the increase in operating income of \$132.7 million, partially offset by the increase in net non-operating expense of \$10.2 million and the increase in the provision for income taxes of \$42.5 million.

Our earnings from continuing operations in the first nine months of 2013 were \$959.9 million compared to earnings from continuing operations of \$778.4 million in the first nine months of 2012. The \$181.5 million increase in earnings from continuing operations was primarily the result of the increase in operating income of \$205.2 million, partially offset by the increase in net non-operating expense of \$1.4 million and the increase in the provision for income taxes of \$22.3 million.

Net Earnings Attributable to Noncontrolling Interest

Our net earnings attributable to noncontrolling interest for our majority-owned subsidiaries were \$1.0 million and \$1.2 million in the third quarter of 2013 and 2012, respectively, and \$4.2 million and \$2.7 million in the first nine months of 2013 and 2012, respectively.

Table of Contents

Discontinued Operations

On February 1, 2013, we completed our previously announced review of strategic options for maximizing the value of our obesity intervention business, and formally committed to pursue a sale of that business unit. As a result of our approved plan to pursue a sale of the obesity intervention business unit, beginning in the first quarter of 2013, we have reported the financial results from that business unit in discontinued operations in the consolidated statements of earnings and have classified the related assets and liabilities as held for sale in the consolidated balance sheet. The prior period consolidated statements of earnings and consolidated balance sheet as of December 31, 2012 have been retrospectively revised to reflect the obesity intervention business unit as discontinued operations and the related assets and liabilities as held for sale. The net assets held for sale include a portion of the medical devices reporting unit's goodwill allocated to the obesity intervention business based on the relative fair value of that business to the portion of the medical devices reporting unit that we will retain.

The results of operations from discontinued operations presented below include certain allocations that management believes fairly reflect the utilization of services provided to the obesity intervention business. The allocations do not include amounts related to general corporate administrative expenses or interest expense. Therefore, the results of operations from the obesity intervention business unit do not necessarily reflect what the results of operations would have been had the business operated as a stand-alone entity.

The following table summarizes the results of operations from discontinued operations:

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	(in millions)			
Product net sales	\$29.3	\$ 37.4	\$94.5	\$ 122.7
Operating costs and expenses:				
Cost of sales (excludes amortization of intangible assets)	5.4	5.8	15.9	18.1
Selling, general and administrative	14.4	18.0	44.8	59.8
Research and development	1.3	3.5	4.0	12.8
Amortization of intangible assets	—	10.4	10.3	30.9
Restructuring charges	—	3.2	—	3.2
Earnings (loss) from discontinued operations before income taxes	\$8.2	\$ (3.5)	\$19.5	\$ (2.1)
Earnings (loss) from discontinued operations, net of income taxes	\$5.5	\$ (2.3)	\$13.1	\$ (1.1)

In the first quarter of 2013, we also reported a separate estimated pre-tax disposal loss of \$346.2 million (\$259.0 million after tax) related to the obesity intervention business unit from the write-down of the net assets held for sale to their estimated fair value less costs to sell.

On October 28, 2013, we entered into a definitive agreement to sell our obesity intervention business to Apollo Endosurgery, Inc., or Apollo, for an upfront cash payment of \$75.0 million, subject to certain adjustments, and certain additional consideration, including a \$15.0 million minority equity interest in Apollo and contingent consideration of up to \$20.0 million to be paid upon the achievement of certain regulatory and sales milestones. The transaction is expected to close in 2013, subject to customary closing conditions. In the third quarter of 2013, we recorded an additional pre-tax disposal loss of \$58.7 million (\$37.6 million after tax) from the write-down of the net assets held for sale to their estimated fair value based on the terms of the sale agreement.

Table of Contents

The following table summarizes the assets and liabilities held for sale related to the obesity intervention business unit as of September 30, 2013 and December 31, 2012:

	September 30, 2013	December 31, 2012
	(in millions)	
Assets:		
Trade receivables, net	\$22.2	\$ 25.2
Inventories	10.1	10.6
Property, plant and equipment, net	1.2	1.4
Goodwill	105.7	105.7
Intangibles, net	358.7	369.0
Other assets	0.3	0.7
Valuation allowance	(404.9) —
Total assets held for sale	\$93.3	\$ 512.6
Liabilities:		
Accounts payable	\$0.8	\$ 0.9
Accrued expenses	2.4	4.1
Other liabilities	0.1	0.3
Total liabilities held for sale	\$3.3	\$ 5.3

Liquidity and Capital Resources

We assess our liquidity by our ability to generate cash to fund our operations. Significant factors in the management of liquidity are: funds generated by operations; levels of accounts receivable, inventories, accounts payable and capital expenditures; the extent of our stock repurchase program; funds required for acquisitions and other transactions; funds available under our credit facilities; and financial flexibility to attract long-term capital on satisfactory terms.

Historically, we have generated cash from operations in excess of working capital requirements. The net cash provided by operating activities for the first nine months of 2013 was \$1,180.1 million compared to \$1,100.0 million for the first nine months of 2012. Cash flow from operating activities increased in the first nine months of 2013 compared to the first nine months of 2012 primarily as a result of an increase in cash from net earnings from operations, including the effect of adjusting for non-cash items, and a decrease in cash required to fund changes in other current assets, accounts payable and other liabilities, partially offset by an increase in cash used to fund changes in trade receivables, inventories, other non-current assets, accrued expenses and income taxes. In September 2012, we terminated the \$300.0 million notional amount interest rate swap and received \$54.7 million, which included accrued interest of \$3.7 million. In the first nine months of 2013 and 2012, we made upfront payments of \$6.5 million and \$62.5 million, respectively, for various licensing and collaboration agreements, which were included in our net earnings for the respective periods. In the first nine months of 2013 and 2012, we paid pension contributions of \$22.0 million and \$23.1 million, respectively, to our U.S. defined benefit pension plan.

Net cash used in investing activities was \$1,262.0 million in the first nine months of 2013 compared to net cash used in investing activities of \$211.4 million in the first nine months of 2012. In the first nine months of 2013, we received \$380.5 million from the maturities of short-term investments. In the first nine months of 2013, we purchased \$644.5 million of short-term investments and paid \$889.7 million, net of cash acquired, for the acquisitions of MAP and Exemplar, and \$2.4 million for purchase price adjustments related to prior acquisitions. Additionally, we invested \$97.4 million in new facilities and equipment and \$8.6 million in capitalized software. In the first nine months of 2012, we received \$604.7 million from the maturities of short-term investments and \$1.3 million from the sale of property, plant and equipment. In the first nine months of 2012, we purchased \$704.6 million of short-term investments, paid \$3.1 million for the purchase of our distributor's business related to our products in Russia and paid \$4.1 million for trademarks and developed technology intangible assets. Additionally, we invested \$98.1 million in new facilities and equipment and \$7.5 million in capitalized software. We currently expect to invest between approximately \$150 million and \$200 million in capital expenditures for manufacturing and administrative facilities,

manufacturing equipment and other property, plant and equipment during 2013.

Net cash provided by financing activities was \$70.8 million in the first nine months of 2013 compared to net cash used in financing activities of \$638.5 million in the first nine months of 2012. On March 12, 2013, we issued concurrently in a registered offering \$250.0 million in aggregate principal amount of our 2018 Notes and \$350.0 million in aggregate principal amount of our

Table of Contents

2023 Notes, and received total proceeds of \$598.5 million, net of original discounts. Additionally, in the first nine months of 2013, we received \$160.1 million from the sale of stock to employees and \$33.6 million in excess tax benefits from share-based compensation. These amounts were partially reduced by the repurchase of approximately 6.1 million shares of our common stock for \$649.3 million, a cash payment of \$4.8 million for offering fees related to the issuance of the 2018 Notes and the 2023 Notes, \$44.6 million in dividends paid to stockholders, net repayments of notes payable of \$11.6 million and payments of contingent consideration of \$11.1 million. In the first nine months of 2012, we repurchased approximately 8.0 million shares of our common stock for \$723.3 million, paid \$45.4 million in dividends to stockholders, made net repayments of notes payable of \$43.1 million and paid contingent consideration of \$5.1 million. This use of cash was partially offset by \$153.9 million received from the sale of stock to employees and \$24.5 million in excess tax benefits from share-based compensation.

Effective October 25, 2013, our Board of Directors declared a cash dividend of \$0.05 per share, payable December 11, 2013 to stockholders of record on November 20, 2013.

We maintain an evergreen stock repurchase program. Our evergreen stock repurchase program authorizes us to repurchase our common stock for the primary purpose of funding our stock-based benefit plans. Under the stock repurchase program, we may maintain up to 18.4 million repurchased shares in our treasury account at any one time. At September 30, 2013, we held approximately 10.4 million treasury shares under this program. In the first quarter of 2013, we completed the repurchase of 6.0 million shares under our previously disclosed Rule 10b5-1 plan. We are uncertain as to the level of stock repurchases, if any, to be made in the future.

Our 5.75% Senior Notes due 2016, or 2016 Notes, were sold at 99.717% of par value with an effective interest rate of 5.79%, pay interest semi-annually on the principal amount of the notes at a rate of 5.75% per annum, and are redeemable at any time at our option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2016 Notes will be due and payable on April 1, 2016, unless earlier redeemed by us. In September 2012, we terminated the \$300.0 million notional amount interest rate swap related to the 2016 Notes and received \$54.7 million, which included accrued interest of \$3.7 million. Upon termination of the interest rate swap, we added the net fair value received of \$51.0 million to the carrying value of the 2016 Notes. The amount received for the termination of the interest rate swap is being amortized as a reduction to interest expense over the remaining life of the debt, which effectively fixes the interest rate for the remaining term of the 2016 Notes at 3.94%.

Our 2018 Notes, which were sold at 99.793% of par value with an effective interest rate of 1.39%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 1.35% per annum, and are redeemable at any time at our option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2018 Notes will be due and payable on March 15, 2018, unless earlier redeemed by us.

Our 3.375% Senior Notes due 2020, or 2020 Notes, which were sold at 99.697% of par value with an effective interest rate of 3.41%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 3.375% per annum, and are redeemable at any time at our option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2020 Notes will be due and payable on September 15, 2020, unless earlier redeemed by us.

Our 2023 Notes, which were sold at 99.714% of par value with an effective interest rate of 2.83%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 2.80% per annum, and are redeemable at any time at our option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption, if the redemption occurs prior to December 15, 2022 (three months prior to the maturity of the 2023 Notes). If the redemption occurs on or after December 15, 2022, then such redemption is not subject to the make-whole provision. The aggregate outstanding principal amount of the 2023 Notes will be due and payable on March 15, 2023, unless earlier redeemed by us.

At September 30, 2013, we had a committed long-term credit facility, a commercial paper program, a shelf registration statement that allows us to issue additional securities, including debt securities, in one or more offerings from time to time, a real estate mortgage and various foreign bank facilities. Our committed long-term credit facility will expire in October 2016. The termination date can be further extended from time to time upon our request and

acceptance by the issuer of the facility for a period of one year from the last scheduled termination date for each request accepted. The committed long-term credit facility allows for borrowings of up to \$800.0 million. The commercial paper program also provides for up to \$800.0 million in borrowings. However, our combined borrowings under our committed long-term credit facility and our commercial paper program may not exceed \$800.0 million in the aggregate. Borrowings under the committed long-term credit facility are subject to certain financial and operating covenants that include, among other provisions, maximum leverage ratios. Certain covenants also limit subsidiary debt. We believe we were in compliance with these covenants at September 30, 2013. At September 30, 2013, we had no borrowings under our committed long-term credit facility, \$20.0 million in borrowings outstanding under the real estate mortgage, \$37.2

Table of Contents

million in borrowings outstanding under various foreign bank facilities and no borrowings under the commercial paper program. Commercial paper, when outstanding, is issued at current short-term interest rates. Additionally, any future borrowings that are outstanding under the long-term credit facility may be subject to a floating interest rate. We may from time to time seek to retire or purchase our outstanding debt.

On September 25, 2013, we announced that we had entered into a license agreement with Medytox, Inc., or Medytox, pursuant to which, upon closing, we will pay Medytox an upfront payment of \$65.0 million and Medytox will grant us exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. The terms of the agreement also include potential future development milestone payments of up to \$116.5 million and potential future sales milestone payments of up to \$180.5 million, as well as potential future royalty payments. The closing of the transaction is contingent on obtaining certain government approvals.

On September 10, 2013, we entered into a license and collaboration agreement with a third party pursuant to which we obtained exclusive global rights to research, manufacture and commercialize certain technologies for the treatment of ocular disease. Under the terms of the agreement, we made a \$6.5 million upfront payment in September 2013. The terms of the agreement also include potential future payments to the third party related to our achievement of development, regulatory and sales milestone events, as well as potential future royalty payments.

On February 1, 2013, we completed our previously announced review of strategic options for maximizing the value of our obesity intervention business, and formally committed to pursue a sale of that business unit. On October 28, 2013, we entered into a definitive agreement to sell our obesity intervention business to Apollo Endosurgery, Inc., or Apollo, for an upfront cash payment of \$75.0 million, subject to certain adjustments, and certain additional consideration, including a \$15.0 million minority equity interest in Apollo and contingent consideration of up to \$20.0 million to be paid upon the achievement of certain regulatory and sales milestones. The transaction is expected to close in 2013, subject to customary closing conditions.

At December 31, 2012, we had net pension and postretirement benefit obligations totaling \$263.2 million. Future funding requirements are subject to change depending on the actual return on net assets in our funded pension plans and changes in actuarial assumptions. In 2013, we expect to pay pension contributions of between \$40.0 million and \$50.0 million for our U.S. and non-U.S. pension plans and between \$1.0 million and \$2.0 million for our other postretirement plan.

Generic versions of Elestat[®] and Sanctura XR[®] were launched in the United States in May 2011 and October 2012, respectively, and a generic version of Zymaxid[®] was launched in the United States in October 2013. In addition, our products compete with generic versions of some branded pharmaceutical products sold by our competitors. We do not believe that our liquidity will be materially impacted in 2013 by generic competition.

As of September 30, 2013, \$2,287.9 million of our existing cash and equivalents and short-term investments are held by non-U.S. subsidiaries. We currently plan to use these funds indefinitely in our operations outside the United States. Withholding and U.S. taxes have not been provided for unremitted earnings of certain non-U.S. subsidiaries because we have reinvested these earnings indefinitely in such operations. At December 31, 2012, we had approximately \$3,083.5 million in unremitted earnings outside the United States for which withholding and U.S. taxes were not provided. Tax costs would be incurred if these earnings were remitted to the United States.

We sell products to public and semi-public hospitals in Italy and Spain, which are wholly or partially funded by their respective sovereign governments. The following table provides information related to trade receivables outstanding as of September 30, 2013 from product net sales in Italy and Spain:

	Italy (in millions)	Spain
Trade receivables from public and semi-public hospitals primarily funded by the sovereign government	\$20.1	\$18.8
Trade receivables from other customers	7.0	16.4
Total trade receivables	\$27.1	\$35.2
Amount of trade receivables that is past due	\$16.8	\$19.6

Allowance for doubtful accounts	\$5.5	\$4.4
---------------------------------	-------	-------

We believe the reserves established against these trade receivables are sufficient to cover the amounts that will ultimately be uncollectible. However, the economic stability in these countries is unpredictable and we cannot provide assurance that additional

Table of Contents

allowances will not be necessary if current economic conditions in these countries continue to decline. Negative changes in the amount of allowances for doubtful accounts could adversely affect our future results of operations. As of September 30, 2013, we have no significant trade accounts receivable from customers in Greece or Portugal that are primarily funded by their respective sovereign governments.

As of September 30, 2013, we had trade receivables from a single commercial distributor in Venezuela of approximately \$44.1 million, which are subject to currency exchange controls administered by the Commission for the Administration of Currency Exchange, or CADIVI, a Venezuelan government body. The payment of our trade receivables is required to be approved through CADIVI's administration of monthly allocations of foreign currency provided by the Central Bank of Venezuela. Our trade receivables are subject to future potential currency devaluation actions that could be taken by the Venezuelan government, which have occurred several times in the past. The agreement with our distributor contains certain terms that partially limit our exposure to devaluation risk, but because of the unpredictable economic stability in Venezuela, our trade receivables in Venezuela may become subject to a material devaluation.

We believe that the net cash provided by operating activities, supplemented as necessary with borrowings available under our existing credit facilities and existing cash and equivalents and short-term investments, will provide us with sufficient resources to meet our current expected obligations, working capital requirements, debt service and other cash needs over the next year.

Table of Contents

ALLERGAN, INC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In the normal course of business, our operations are exposed to risks associated with fluctuations in interest rates and foreign currency exchange rates. We address these risks through controlled risk management that includes the use of derivative financial instruments to economically hedge or reduce these exposures. We do not enter into derivative financial instruments for trading or speculative purposes.

To ensure the adequacy and effectiveness of our interest rate and foreign exchange hedge positions, we continually monitor our interest rate swap positions and foreign exchange forward and option positions both on a stand-alone basis and in conjunction with our underlying interest rate and foreign currency exposures, from an accounting and economic perspective.

However, given the inherent limitations of forecasting and the anticipatory nature of the exposures intended to be hedged, we cannot assure you that such programs will offset more than a portion of the adverse financial impact resulting from unfavorable movements in either interest or foreign exchange rates. In addition, the timing of the accounting for recognition of gains and losses related to mark-to-market instruments for any given period may not coincide with the timing of gains and losses related to the underlying economic exposures and, therefore, may adversely affect our consolidated operating results and financial position.

As of September 30, 2013, we had no interest rate swap contracts outstanding. However, we may from time to time seek to enter into interest rate hedge transactions in the future.

Interest Rate Risk

Our interest income and expense are more sensitive to fluctuations in the general level of U.S. interest rates than to changes in rates in other markets. Changes in U.S. interest rates affect the interest earned on our cash and equivalents and short-term investments and interest expense on our debt, as well as costs associated with foreign currency contracts.

On January 31, 2007, we entered into a nine-year, two-month interest rate swap with a \$300.0 million notional amount. The swap received interest at a fixed rate of 5.75% and paid interest at a variable interest rate equal to 3-month LIBOR plus 0.368%, and effectively converted \$300.0 million of the \$800.0 million aggregate principal amount of our 2016 Notes to a variable interest rate. Based on the structure of the hedging relationship, the hedge met the criteria for using the short-cut method for a fair value hedge. In September 2012, we terminated the interest rate swap and received \$54.7 million, which included accrued interest of \$3.7 million. Upon termination of the interest rate swap, we added the net fair value received of \$51.0 million to the carrying value of the 2016 Notes. The amount received for the termination of the interest rate swap is being amortized as a reduction to interest expense over the remaining life of the debt, which effectively fixes the interest rate for the remaining term of the 2016 Notes at 3.94%. During the three and nine month periods ended September 30, 2013, we recognized \$3.3 million and \$9.8 million, respectively, as a reduction of interest expense due to the effect of the interest rate swap. During the three and nine month periods ended September 30, 2012, we recognized \$3.2 million and \$10.6 million, respectively, as a reduction of interest expense due to the effect of the interest rate swap.

In February 2006, we entered into interest rate swap contracts based on 3-month LIBOR with an aggregate notional amount of \$800.0 million, a swap period of 10 years and a starting swap rate of 5.198%. We entered into these swap contracts as a cash flow hedge to effectively fix the future interest rate for our 2016 Notes. In April 2006, we terminated the interest rate swap contracts and received approximately \$13.0 million. The total gain is being amortized as a reduction to interest expense over a 10 year period to match the term of the 2016 Notes. As of September 30, 2013, the remaining unrecognized gain, net of tax, of \$2.0 million is recorded as a component of accumulated other comprehensive loss.

At September 30, 2013, we had approximately \$37.2 million of variable rate debt. If interest rates were to increase or decrease by 1% for the year, annual interest expense would increase or decrease by approximately \$0.4 million. Commercial paper, when outstanding, is issued at current short-term interest rates. Additionally, any future borrowings that are outstanding under the long-term credit facility may be subject to a floating interest rate. Therefore, higher interest costs could occur if interest rates increase in the future.

Table of Contents

The following tables present information about certain of our investment portfolio and our debt obligations at September 30, 2013 and December 31, 2012.

	September 30, 2013						Total	Fair Market Value
	Maturing in							
	2013	2014	2015	2016	2017	Thereafter		
(in millions, except interest rates)								
ASSETS								
Cash Equivalents and Short-Term Investments:								
Commercial Paper	\$1,641.2	\$—	\$—	\$—	\$—	\$—	\$1,641.2	\$1,641.2
Weighted Average Interest Rate	0.09	% —	—	—	—	—	0.09	%
Foreign Time Deposits	312.9	—	—	—	—	—	312.9	312.9
Weighted Average Interest Rate	0.14	% —	—	—	—	—	0.14	%
Other Cash Equivalents	1,022.6	—	—	—	—	—	1,022.6	1,022.6
Weighted Average Interest Rate	0.21	% —	—	—	—	—	0.21	%
Total Cash Equivalents and Short-Term Investments	\$2,976.7	\$—	\$—	\$—	\$—	\$—	\$2,976.7	\$2,976.7
Weighted Average Interest Rate	0.13	% —	—	—	—	—	0.13	%
LIABILITIES								
Debt Obligations:								
Fixed Rate (US\$) (a)	\$—	\$—	\$—	\$834.3	\$20.0	\$1,247.2	\$2,101.5	\$2,181.4
Weighted Average Interest Rate	—	—	—	3.94	% 5.65	% 2.84	% 3.31	%
Other Variable Rate (non-US\$)	37.2	—	—	—	—	—	37.2	37.2
Weighted Average Interest Rate	6.82	% —	—	—	—	—	6.82	%
Total Debt Obligations	\$37.2	\$—	\$—	\$834.3	\$20.0	\$1,247.2	\$2,138.7	\$2,218.6
Weighted Average Interest Rate	6.82	% —	—	3.94	% 5.65	% 2.84	% 3.37	%

(a) The carrying value of debt obligations maturing in 2016 includes an unamortized amount of \$34.8 million related to a terminated interest rate swap associated with the 2016 Notes.

Table of Contents

	December 31, 2012 Maturing in						Total	Fair Market Value
	2013	2014	2015	2016	2017	Thereafter		
(in millions, except interest rates)								
ASSETS								
Cash Equivalents and Short-Term Investments:								
Commercial Paper	\$1,709.0	\$—	\$—	\$—	\$—	\$—	\$1,709.0	\$1,709.0
Weighted Average Interest Rate	0.14	%	—	—	—	—	0.14	%
Foreign Time Deposits	341.7	—	—	—	—	—	341.7	341.7
Weighted Average Interest Rate	0.17	%	—	—	—	—	0.17	%
Other Cash Equivalents	685.0	—	—	—	—	—	685.0	685.0
Weighted Average Interest Rate	0.17	%	—	—	—	—	0.17	%
Total Cash Equivalents and Short-Term Investments	\$2,735.7	\$—	\$—	\$—	\$—	\$—	\$2,735.7	\$2,735.7
Weighted Average Interest Rate	0.15	%	—	—	—	—	0.15	%
LIABILITIES								
Debt Obligations:								
Fixed Rate (US\$) (a)	\$—	\$—	\$—	\$843.9	\$20.0	\$648.5	\$1,512.4	\$1,673.0
Weighted Average Interest Rate	—	—	—	3.94	% 5.65	% 3.41	% 3.74	%
Other Variable Rate (non-US\$)	48.8	—	—	—	—	—	48.8	48.8
Weighted Average Interest Rate	6.06	%	—	—	—	—	6.06	%
Total Debt Obligations	\$48.8	\$—	\$—	\$843.9	\$20.0	\$648.5	\$1,561.2	\$1,721.8
Weighted Average Interest Rate	6.06	%	—	3.94	% 5.65	% 3.41	% 3.81	%

(a) The carrying value of debt obligations maturing in 2016 includes an unamortized amount of \$44.6 million related to a terminated interest rate swap associated with the 2016 Notes.

Foreign Currency Risk

Overall, we are a net recipient of currencies other than the U.S. dollar and, as such, benefit from a weaker dollar and are adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect our consolidated revenues or operating costs and expenses as expressed in U.S. dollars.

From time to time, we enter into foreign currency option and forward contracts to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow our management to focus its attention on our core business issues. Accordingly, we enter into various contracts which change in value as foreign exchange rates change to economically offset the effect of changes in the value of foreign currency assets and liabilities, commitments and anticipated foreign currency denominated sales and operating expenses. We enter into foreign currency option and forward contracts in amounts between minimum and maximum anticipated foreign exchange exposures, generally for periods not to exceed 18 months.

We use foreign currency option contracts, which provide for the sale or purchase of foreign currencies, to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of our business. Probable but not firmly committed transactions are comprised primarily of sales of products and purchases of raw material in currencies other than the U.S. dollar. The foreign currency option contracts are entered into to reduce the volatility of earnings generated in currencies other than the U.S. dollar, primarily earnings denominated in the Canadian dollar, Mexican peso, Australian dollar, Brazilian real, euro, Korean won, Turkish lira, Polish zloty, Swiss franc, Russian ruble, Swedish krona and South African rand. While these instruments are subject to fluctuations in value, such fluctuations are anticipated to offset changes in the value of the underlying exposures. Changes in the fair value of open foreign currency option contracts and any realized gains (losses) on settled contracts are recorded through earnings as "Other, net" in the accompanying unaudited condensed consolidated statements of earnings. The premium costs of purchased foreign exchange option contracts are recorded in "Other current assets" and amortized to "Other, net" over the life of the options.

All of our outstanding foreign exchange forward contracts are entered into to offset the change in value of certain intercompany receivables or payables that are subject to fluctuations in foreign currency exchange rates. The realized and unrealized

Table of Contents

gains and losses from foreign currency forward contracts and the revaluation of the foreign denominated intercompany receivables or payables are recorded through "Other, net" in the accompanying unaudited condensed consolidated statements of earnings.

The following table provides information about our foreign currency derivative financial instruments outstanding as of September 30, 2013 and December 31, 2012. The information is provided in U.S. dollars, as presented in our unaudited condensed consolidated financial statements:

	September 30, 2013		December 31, 2012	
	Notional Amount (in millions)	Average Contract Rate or Strike Amount	Notional Amount (in millions)	Average Contract Rate or Strike Amount
Foreign currency forward contracts: (Receive U.S. dollar/pay foreign currency)				
Japanese yen	\$9.6	99.23	\$8.3	83.88
Australian dollar	15.3	0.93	17.3	1.05
Russian ruble	20.5	32.75	17.9	31.31
New Zealand dollar	0.8	0.81	—	—
Polish zloty	—	—	1.1	3.14
	\$46.2		\$44.6	
Estimated fair value	\$(0.1)	\$0.3	
Foreign currency forward contracts: (Pay U.S. dollar/receive foreign currency)				
Euro	\$40.1	1.34	\$39.6	1.32
Estimated fair value	\$0.5		\$—	
Foreign currency sold — put options:				
Canadian dollar	\$111.9	1.03	\$105.6	1.02
Mexican peso	5.1	13.27	17.8	13.10
Australian dollar	62.9	0.93	67.9	1.00
Brazilian real	42.4	2.36	45.5	2.14
Euro	159.9	1.32	168.0	1.29
Korean won	5.4	1,091.68	20.1	1,086.16
Turkish lira	6.8	1.86	27.0	1.83
Polish zloty	2.5	3.22	8.7	3.19
Swiss franc	2.3	0.92	8.6	0.92
Russian ruble	1.9	32.46	10.6	31.74
Swedish krona	2.7	6.72	9.7	6.70
South African rand	3.2	9.09	12.1	8.94
	\$407.0		\$501.6	
Estimated fair value	\$10.9		\$9.9	

Table of Contents

ALLERGAN, INC.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and our Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Our management, including our Principal Executive Officer and our Principal Financial Officer, does not expect that our disclosure controls or procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, we have investments in certain unconsolidated entities. As we do not control or manage these entities, our disclosure controls and procedures with respect to such entities are necessarily substantially more limited than those we maintain with respect to our consolidated subsidiaries.

We carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013, the end of the quarterly period covered by this report. Based on the foregoing, our Principal Executive Officer and our Principal Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective and were operating at the reasonable assurance level.

Further, management determined that, as of September 30, 2013, there were no changes in our internal control over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

ALLERGAN, INC.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Certain of the legal proceedings in which we are involved are discussed in Note 11, "Contingencies," to our Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q, and are hereby incorporated by reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed by us in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as supplemented and amended by the risk factors previously disclosed by us in Part II, Item 1A "Risk Factors" of our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2013 and June 30, 2013.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table discloses the purchases of our equity securities during the third fiscal quarter of 2013.

Period	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs (2)
July 1, 2013 to July 31, 2013	—	\$—	—	7,701,424
August 1, 2013 to August 31, 2013	2,155	91.95	—	7,841,748
September 1, 2013 to September 30, 2013	—	—	—	7,992,630
Total	2,155	\$91.95	—	N/A

We maintain an evergreen stock repurchase program, which we first announced on September 28, 1993. Under the stock repurchase program, we may maintain up to 18.4 million repurchased shares in our treasury account at any (1) one time. At September 30, 2013, we held approximately 10.4 million treasury shares under this program. Total number of shares purchased represents shares of common stock withheld by us to satisfy tax withholding obligations related to vested employee restricted stock awards.

(2) The share numbers reflect the maximum number of shares that may be purchased under our stock repurchase program and are as of the end of each of the respective periods.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Reference is made to the Exhibit Index included herein.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 5, 2013

ALLERGAN, INC.

/s/ Jeffrey L. Edwards
Jeffrey L. Edwards
Executive Vice President,
Finance and Business Development,
Chief Financial Officer
(Principal Financial Officer)

Table of Contents

ALLERGAN, INC.

EXHIBIT INDEX

Exhibit No.	Description
3.1	Amended and Restated Certificate of Incorporation of Allergan, Inc. (incorporated by reference to Exhibit 3.1 to Allergan Inc.'s Report on Form 10-Q for the Quarter ended March 31, 2013)
3.2	Allergan, Inc. Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Allergan Inc.'s Report on Form 10-Q for the Quarter ended March 31, 2013)
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended
32	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350
101	The following financial statements from Allergan, Inc.'s Report on Form 10-Q for the Quarter ended September 30, 2013, formatted in XBRL (eXtensible Business Reporting Language): (i) Unaudited Condensed Consolidated Statements of Earnings; (ii) Unaudited Condensed Consolidated Statements of Comprehensive Income; (iii) Unaudited Condensed Consolidated Balance Sheets; (iv) Unaudited Condensed Consolidated Statements of Cash Flows; and (v) Notes to Unaudited Condensed Consolidated Financial Statements

60